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Renal cell carcinoma (RCC) patients are routinely treated with cytokines and VEGF 
targeted anti-angiogenics. Resistance to therapy due to the by-passing of VEGF pathway and 
severe systemic side effects induced by cytokines and VEGF targeting pose major drawbacks. 
Melanoma cell adhesion molecule (MCAM) is a marker of RCC blood vessels, with low or no 
expression on healthy vasculature. This thesis aimed to generate mouse MCAM targeted 
antibodies and recombinant human MCAM extracellular domain (hMCAMecd) receptor trap 
to investigate MCAM as a potential therapeutic target. Around 50 anti-mouse MCAM 
hybridoma clones were generated from immunized rats, with two of them sub-cloned to 
stable antibody expressing hybridomas (mMCAM10 and mMCAM66). The two antibodies 
recognize mMCAM by flow cytometry, immunohistochemistry, Western blot and 
immunoprecipitation. The mMCAM10, but not the mMCAM66, localises to tumour vessels 
within one hour of intravenous injection into the tumour bearing mice. This indicates MCAM’s 
potential as a target for tumour vascular disruption. The variable region of the mMCAM10 
was sequenced for future antibody engineering. The hMCAMecd fused to an Fc tag caused 
significant reduction in endothelial cell migration, tube formation and transmigration, and had 
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1.1 General introduction 
Cancer treatment has become much advanced with the development of targeted 
therapy in the course of last two decades. By taking advantage of biological features of cancer 
cells and their changed environment, the much-needed reduction in systemic negative effects 
on the healthy tissue was accomplished. Specific targeting of tumour related molecules posed 
great advantage over traditional chemotherapy and radiotherapy and improved survival and 
disease stabilisation of many cancer patients. Data generated from large numbers of clinical 
trials using targeted therapies accomplished exponential success and is continuing to improve 
both clinical output in the sense of patient benefit as well as enhancing the knowledge of 
cancer biology. However, better understanding of several aspects such as cancer progression 
mechanisms, development of resistance to therapy and patient stratification is still much 
needed in order to further improve cancer treatment. Therefore, every new approach is a step 
closer to finding cure for this diverse and complex disease.  
This thesis will focus on generation and characterisation of targeted therapy for renal 
cell carcinoma, by targeting Melanoma Cell Adhesion Molecule (MCAM), which is highly 
expressed on tumour blood vessels and correlates with poor patient prognosis. It will explore 
the potential of MCAM as a target for tumour vessel disruption using monoclonal antibodies 
to MCAM, as well as potential of soluble recombinant MCAM extracellular domain fused to 









1.2 Monoclonal antibodies and their use in research and clinic 
Antibodies are widely used and valuable tools in life science, however they can be 
problematic with a number of characteristics that have to be verified such as cross-reactivity, 
the strength of affinity and stability in experimental conditions, in order for their proper use 
1. Well-characterised antibodies, both polyclonal and monoclonal, provide valuable resources 
in research. Furthermore, monoclonal antibodies are increasingly being introduced into 
clinical setting as treatment tools for various conditions including cancer 2–4.  
Antibodies are formed of two heavy and two light chains connected by disulphide 
bonds. Both heavy and light chains contain a constant region and a variable region with 
antigen binding specificity. The constant region of heavy chain is involved in the immune 
effector function by binding to and activating immune system components via Fc receptors. 
The variable regions are formed by gene rearrangements creating three complementarity-
determining regions on both the heavy and light chain, which then together form an antigen-
binding site. Gene rearrangements in B-cells are capable of generating around 200 million 
different antigen binding regions, but each B-cell contains only one. Once the specific antigen 
is present in the body, B-cell with affinity to that antigen will be activated and start producing 
antibodies. Cells with reactivity to self-protein are deleted in early development in the B-cell 
maturation sites, where cells die upon binding the self-antigen 5,6.  
1.2.1. Antibodies in cancer targeted therapies and mechanisms of action 
Antibodies are unique because of their high specificity and several mechanisms of 
action based on the targeted antigen and immune effector functions. When binding the 








dependent phagocytosis by binding and activating receptors on immune cells, or initiate 
complement dependent cytotoxicity by recruiting proteins of the complement system. 
Antibodies can also block the receptor function, abrogate signalling, induce internalisation 
and receptor down-regulation or directly induce cell apoptosis 7,8. The host antibody immune 
response in cancer is dependent on the presentation of neo-antigens that arise from 
mutations in tumour proteins or in some cases expression of foetal antigens that are silenced 
in the adult, and to which B-cells have not been deleted 9. This ability of immune system has 
been shown to protect against cancer development if the cancer can be recognised as foreign. 
However, tumours often evolve to express regulatory proteins which inhibit effective immune 
response 10. Thus, much research has been focused on how to promote immune system in the 
fight against cancer by activating its components or blocking the immune checkpoint proteins 
expressed by the tumour. Major breakthrough was the development of monoclonal antibody 
(mAb) hybridoma technology in 1975 that allowed generation of clonal antibodies targeting 
almost any known biological substance 11. Initially antibodies were produced in laboratory 
animals and so they could not be used in humans due to immunogenicity of immunoglobulins. 
The innovation in a form of grafting complementarity-determining regions of monoclonal 
antibodies to human immunoglobulin backbone 12 enabled the use of antibodies in clinical 
setting without inducing a patient’s immune response. Ever since, a plethora of antibody-
targeted therapies have been generated and are in clinical trials, with more than a dozen being 
approved by the US food and drug administration (FDA) to date.  
Furthermore, antibody engineering led to development of antibodies with modified 
constant regions in order to enhance or decrease activation of immune cells or complement 








specific therapy that uses antibodies to specifically deliver a toxic drug to the antigen 
presenting tissue. The antigen binding regions of antibodies can be cloned into chimeric 
antigen receptor in T cells (CAR-T), which can then be introduced into a patient.  
A major breakthrough in haematological malignancy treatment was introduction of 
the first monoclonal antibody approved for cancer treatment, Rituximab (mAb to CD20), in 
1997. The binding of rituximab to CD20 expressed on all B-cells induces cell apoptosis, having 
a cytotoxic effect both on cancer and healthy cells. Furthermore, antibodies targeting antigens 
HER2 and EGFR on solid tumours also showed a remarkable success in several tumour types. 
Trastuzumab (an antibody to HER2) in combination with another anti-HER2 antibody 
(pertuzumab) against a different epitope showed synergistic improvement in patients’ 
response and overall survival with 50% of patients experiencing complete response in HER2 
positive non-metastatic breast cancer 13. Besides targeting tumour cells, antibodies have been 
developed against the stroma components. One of the most used antibodies against stroma 
is Bevacizumab, an antibody specific for soluble vascular endothelial growth factor - A (VEGF-
A)14. Bevacizumab acts by binding and sequestering VEGF, reducing tumour angiogenesis and 
in some cases normalising tumour blood vessels. The effect of Bevacizumab on vessel 
normalisation induces a therapeutic window in which chemotherapy can be effectively 
delivered to the tumour, having more potent effect than chemotherapy alone. The latest 
success in harnessing immune system to treat cancer is development of antibodies against 
immune checkpoint proteins CTLA-4, PD-1 and PD-L1 3,15. These proteins down-regulate 
immune responses and are often expressed by tumour and immune cells infiltrating the 








Despite the proven success and potential of antibodies in cancer treatment, several 
drawbacks leave room for much further improvement. One of the most important aspects of 
antibody targeting is the selection of a good target. Antibodies to CD20 or CD52 target lineage 
proteins expressed in equal amounts on healthy and cancer cells, eradicating all immune cells 
and causing the lack of functional immune system as well as cytokine release related toxicities. 
Furthermore, these antigens are not crucial for cancer progression, and so the tumours can 
evolve to down-regulate the expression of this antigen causing resistance to therapy. 
Antibodies targeting VEGF, HER2 or EGFR have toxic effects on healthy tissue due to 
involvement of these proteins in vital homeostatic processes 16–18. Much effort is thus invested 
in finding tumour markers with specific expression on the tumour cells or stroma. Lastly, 
targeting immune system regulating proteins causes increase in autoimmune toxicities, and is 
only effective if the immune cells with specificity against cancer antigens are present in the 









1.3 Targeting tumour vessels: anti-angiogenics and vascular disrupting 
agents 
Once a tumour grows beyond 1 mm3 the cells are no longer able to access oxygen and 
dispose of metabolic by-products and the environment becomes hypoxic. Hypoxia triggers 
many signalling pathways in cancer cells, resulting in, amongst others, secretion of pro-
angiogenic factors. New vessels then invade from the existing vasculature causing the 
‘angiogenic switch’ 19,20, a critical step for cancer progression.  
In normoxia (1-4% O2), the VHL protein acts as a negative regulator of HIF-1 
transcription factor. When oxygen is present, prolyl hydroxylases (PHD1–3, prolyl hydroxylase 
domain 1–3) hydroxylate two prolines on HIF-1α protein (Pro402 and Pro564). VHL then 
recognises and binds these residues, marking HIF-1α for degradation. This process is highly 
dependent on the level of molecular oxygen in cells 21,22. In poorly perfused tissues oxygen 
levels are low, prolines are not hydroxylated and proteasomal destruction of HIF-1α does not 
occur. HIF-1α levels increase and can now bind to HIF-1β, located in the nucleus 23 (Figure 1.1 
– schematic representation of HIF pathway in normoxic and hypoxic conditions). The HIF-1 
heterodimer then mediates expression of vast amount of genes involved in angiogenesis, 
survival, cellular metabolism and cell migration 24–26. Amongst other significant genes, HIF-1 
induces overexpression of VEGF-A 27. VEGF-A plays a significant role in angiogenesis by 
stimulating sprouting of new blood vessels from the existing ones. In tumours the expression 
of VEGF-A as well as other growth factors is abnormally high due the fast growth of tumours, 
which induces hypoxic conditions. Thus, constant exposure to high pro-angiogenic signalling 
and lack of homeostatic feedback regulation causes abnormal formation of new blood vessels. 








hypoglycaemia) hugely affect tumour vasculature causing lack of hierarchical arrangements, 
poor mural cell coverage, vessel enlargement and leakage, and poor perfusion. These 
conditions result in low oxygenation, a feature that often causes failure of administered 
chemotherapy and radiotherapy 28. However, these differences cause expression of proteins 
on tumour vessels that might not be expressed on healthy vessels, making them useful targets 
for cancer treatment.  
Blocking tumour angiogenesis or destroying tumour blood vessels is considered a 
promising approach for cancer therapy due to a number of advantages over targeting tumour 
cells: the molecules on tumour vessels are easily accessible to intravenously administered 
agents; endothelial cells are not genetically unstable like cancer cells, so are less likely to 
develop resistance via mutation; and disturbance of blood vessel can cause damage to many 
tumour cells. So far, the major approach has been inhibition of angiogenesis through targeting 


















Figure 1.1 VHL regulation during normal oxygen levels and in hypoxia. During normal oxygen levels 
in the tissue VHL protein recognises hydroxylated prolines on HIF-1a transcription factor and marks it 
for protein degradation, while during hypoxic conditions or in case of inactivated VHL protein HIF-1a 
remains stable and binds HIF-1b in the nucleus. The HIF-1 dimer affects expression of numerous 










Renal cell carcinoma  
Renal cell carcinoma (RCC) is the most frequent form of kidney cancer, comprising 
around 85% of all cases. The remaining 15% of kidney cancers are urothelial carcinoma, 
sarcoma, Wilms tumour and lymphoma. Statistically, kidney cancer is the 12th most common 
cancer in the world, but 9th most common cancer in the more developed countries (North 
America, Europe, Australia and New Zealand) 29. This is due to higher rates of smoking and 
‘fast-food’ diets high in unhealthy fat, both of which increase the risk of renal cancer 30. The 
diseases mostly develops in older people with an average age of diagnosis of 64, and is more 
frequent in men than women 31. Moreover, the occurrence of kidney cancer increases yearly 
32, for example a 41% increase from 2003 to 2014 has been reported in the UK 33, and a further 
increase of 26% is expected in the next 12 years. 
Renal cell carcinoma predominantly presents with clear cell histology (ccRCC), which 
is in 90% of cases connected to the loss of function of the VHL gene 34. In around 50% of RCC 
sporadic mutations or deletions of the VHL gene are observed in both alleles, and other cases 
fail to express the VHL protein due to epigenetic hypermethylation of the VHL gene 35. 
Hereditary mutation of the VHL gene is called the VHL syndrome and patients with this 
syndrome have a tendency to develop RCC, and other highly vascular tumours at a much 
younger age 36. VHL syndrome is an autosomal dominant genetic disorder due to mutation in 
one allele of the VHL gene when there is a subsequent loss or mutation in the remaining VHL 
allele 37,38. VHL inactivation in RCC creates an environment in which angiogenesis is 
continuously activated via production of VEGF-A without the need for hypoxic conditions, 








1.3.1. Treatment of RCC 
Renal cell carcinoma often presents with minimal or generic symptoms such as slight 
abdominal or lower back pain and is thus, often detected at a late stage. The current standard 
of care for localised RCC is surgical resection and subsequent monitoring for progression 39,40. 
Early stage RCC patients have a 74% chance of 5-year survival. However, progressed disease 
is often hard to treat with the approved treatments, and complete response is seen in a 
disappointingly small number of patients, around 1-3% 41. Moreover, around 30% of patients 
with localised disease will experience recurrence during their lifetime 42 and the 5 year survival 
rate drops drastically for patients with advanced or metastatic disease to only 8% 31. 
Traditional forms of therapy (chemotherapy and radiotherapy) have proven inefficient 
in the treatment of RCC. However, based on several observations of spontaneous remission 
in cases with progressed RCC, it was postulated that the host immune system could be 
activated to target and eradicate the cancer 43. Subsequently, cytokine based therapies IFN-a 
and IL-2 demonstrated an effect on survival in some patients with progressive metastatic 
disease 44. However, no significant benefit on survival was observed for patients with locally 
advanced RCC with high risk of recurrence after nephrectomy 45. These therapies are 
significantly more effective in higher doses, but unfortunately induce severe immune system 
related side effects 46, which can cause serious damage and have proved fatal in some cases 
47. Therefore, their use is often restricted to younger patients with good performance status. 
Furthermore, complete response is observed in only 7% of patients receiving high doses of IL-
2 48.  
In 2005 the first targeted therapy was approved for the treatment of RCC. Using 








to previous systemic therapies and led to approval of several anti-angiogenic drugs, mTOR 
inhibitors and targeted immunotherapy. However, targeting angiogenesis is the preferred first 
line option for advanced and metastatic RCC, specifically in cases with clear cell histology. 
Once the patient progresses on anti-angiogenics, the second line treatment includes other 
type of anti-angiogenic drug, mTOR inhibitor or targeted immunotherapy depending on the 
patient’s status and pathology of the tumour 49. 
1.3.2. Anti-angiogenic therapy in RCC 
Sunitinib, a tyrosine kinase inhibitor (TKI), was the first anti-angiogenic drug approved 
for first line treatment of metastatic RCC due to a significant improvement in progression free 
survival when compared to cytokine therapy in untreated patients 50. Pazopanib, another TKI, 
was also approved for the first line treatment in advanced RCC, after showing a 5-month 
improvement in progression free survival when compared with placebo in patients that were 
untreated as well as in those progressed after cytokine therapy 51. Sorafenib, axitinib, 
cabozantinib, and lenvatinib are other approved TKIs for RCC treatment. Bevacizumab, an 
antibody that sequesters VEGF protein, is approved in combination with IFN-a for first line 
setting 52, however is rarely used in UK due to its high cost. Yearly improvement in targeted 
therapies can be seen in the latest successful trial testing cabozantinib with sunitinib, showing 
a further increase in progression free survival in patients presented with poor prognosis RCC 
in a first line treatment setting 53. Due to this cabozantinib was approved in December 2017 









1.3.3. Combinational therapeutic approaches 
Combining different strategies to improve the outcome of patients has proven 
beneficial in some cases. Targeting different aspects such as the VEGF pathway together with 
activation of immune system with cytokines by using Bevacizumab together with cytokine IFN-
a had improved PFS when compared with the cytokine therapy alone (10.2 and 5.4 months, 
respectively) 52.  
Combination of lenvatinib with an mTOR inhibitor everolimus presented superior 
overall response rate (ORR) than the everolimus therapy alone (43% versus 6%, respectively) 
54. The PFS and OS were significantly increased as well, and it was approved in 2016 as a 
combination therapy for patients that progressed after anti-VEGF treatment. However, 
another trial that investigated combinations of temsirolimus (mTOR inhibitor) and 
Bevacizumab, in comparison to single agent therapies showed no significant difference in PFS 
and OS, but the grade 3-4 side effects were significantly more frequent in the combination 
group. Many on-going clinical trials are focusing on optimizing combinations and sequencing 
of different agents in order to establish the maximum benefit approach in treating advanced 
and metastatic RCC.  
1.3.4. Future directions based on present knowledge 
Finding appropriate targets and marker molecules in order to develop tools for 
treatment and prediction of disease progression remains a great challenge. 
Notwithstanding all of the recent advances in therapies, there are still numerous 
unanswered questions regarding markers for optimal treatment selection and prediction of 
disease progression. There is an unmet need for improved treatments with fewer and less 








Further research on predictive biomarkers will help in the effort to treat each patient’s tumour 
with individualized therapy 55.  
Screening for molecules expressed by tumour or stromal cells are providing a platform 
of novel molecules that can be used as targets on RCC. Specifically, interesting proteins would 
be ones that are differentially expressed on the pathological tissue and absent or lowly 
expressed on the healthy tissue. Furthermore, proteins that are not relevant for healthy tissue 
homeostasis are preferred, as targeting those molecules would cause less damage to healthy 
organs. VEGF and receptor tyrosine kinases are present in most tissues and are important for 
homeostasis, and thus targeted therapies against those molecules affect the healthy tissue 
and cause systemic side effects.  
Wragg et al.56 screened for differences between tumour vessels of RCC and healthy 
blood vessels in order to identify specific tumour endothelial markers. They isolated 
endothelial cells from matched healthy and tumour tissue taken during nephrectomy of 
patients that had received no therapy prior to surgery. RNA from cells was analysed using 
whole human genome expression microarrays. Besides finding of ‘expected’ upregulated 
genes in tumour angiogenesis they found MCAM (melanoma cell adhesion molecule) and its 
ligand LAMA4 (laminin alpha 4) to be highly expressed in RCC blood vessels, but absent from 
the healthy vessels taken from the same patients. LAMA4 is an extracellular matrix protein, 
which is a component of basal lamina and MCAM is a cell adhesion molecule involved in 
tumour angiogenesis and metastasis in several tumours (described in detail below).  
Wragg et al. confirmed these findings by qRT-PCR and immunostaining, where they 
showed strong MCAM staining of the tumour vessels, whereas no staining was observed in 








healthy tissue of 18 different tumours. MCAM expression was specific for vasculature, except 
in melanoma, where MCAM was expressed on tumour cells. MCAM had strong expression in 
90% of RCC and some of the other cancers while it was absent from the healthy tissue 





















1.4 Melanoma cell adhesion molecule – MCAM 
1.4.1. MCAM gene and protein description 
MCAM (also known as CD146, MUC18, S-Endo1, A32 antigen) is a multifunctional 
protein expressed on the cell surface of several cell types including cancer and tumour 
endothelial cells. The 113 kDa-protein has a single transmembrane domain, short cytoplasmic 
tail and an extracellular domain that consist of characteristic immunoglobulin-like V–V–C2–
C2–C2 domains 57,58. Each of the immunoglobulin domains contains a single intra-chain 
disulphide bond, and the extracellular domain undergoes post-translational glycosylation 59,60. 
Orthologous of MCAM have been identified in other mammalian species (mouse, rat, canine) 
58,61, in avian species also known as HEMCAM or gicerin 62,63, and in fish 64. The human MCAM 
gene has a single copy on chromosome 11 and to date only one mRNA of around 3.3 kb has 
been identified 59,65,66. However, three different mRNA isoforms have been described in 
chicken: MCAM long, MCAM short and soluble MCAM 67. The longer isoform of MCAM 
(lgMCAM) is present in all the species and consists of the extracellular domain, 
transmembrane domain and a cytoplasmic domain which contains two protein kinase C (PKC) 
recognition sites and an ERM (ezrin/radixin/moesin) binding site. The shorter MCAM isoform 
(shMCAM) has a deletion in the cytoplasmic region, causing a reading frame shift that results 
in loss of one of the PKC binding regions. The third MCAM isoform is a soluble extracellular 
domain (sMCAM), which, in chicken, is produced by mRNA splicing 67. Soluble MCAM has been 
found in human plasma and in HUVECs supernatants 68, however there is no evidence that 
this protein is a product of RNA splicing. Rather, evidence shows that this is due to the 








1.4.2. MCAM expression in healthy tissue 
MCAM has been found expressed in numerous tissues during embryonic development, 
such as kidney, retina and the nervous system 63,70,71. However, its expression hugely 
diminishes in adult tissue. Immunohistochemistry with MUC18 antibody showed limited 
expression of MCAM, detected only on smooth muscle cells of vessels, on hair follicles 65 and 
in a small percentage of capillaries, but absent from larger vessels 72. Another antibody to 
MCAM, A32, confirmed this expression pattern 60. In contrast, S-Endo-1 anti-MCAM 
monoclonal antibody, developed against human endothelium, detected MCAM expression on 
all vessels in human tissue regardless of the vessel size or location 73.  
MCAM was further found to be expressed on a subset of nonhaematopoietic bone 
marrow mesenchymal stem cells 74,75, on a small population of T and B lymphocytes and NK 
cells with an effector memory cell phenotype 76, and on CD4+ Th17 and CD8+ Tc17 
lymphocytes with higher affinity for endothelium 77,78. MCAM is also expressed on 
intermediate trophoblast 79,80. In mice, ME-9F1 antibody to mouse protein identified MCAM 
expression on endothelial cells and on a subset of mature NK cells with reduced cytotoxicity 
81,82. 
1.4.3. MCAM expression in cancer and other pathological conditions 
The first discovery of MCAM was with MUC18 antibody in 1987, showing upregulated 
expression on malignant melanoma and in metastasis when compared to healthy melanocytes 
and benign melanoma lesions 65. Much further research on MCAM involvement in melanoma 
confirmed that MCAM is an excellent predictor of melanoma progression with higher 
confidence rate than tumour grade or lymph node 83,84. Besides melanoma, MCAM expression 








85,86, epithelial ovarian cancer 87,88, gastric cancer 89, breast cancer 90,91, kidney cancers 56 and 
non-small-cell lung cancer (NSCLC) 92. However, it does not correlate with tumour progression 
and metastasis in all cases. For example studies in breast cancer are mixed, with several 
studies showing the opposite effect of MCAM on progression and metastatic potential of 
tumour cells, showing more compact and tightly bound cells 93,94. Similarly MCAM is 
considered a tumour suppressor in naso-pharyngeal carcinoma 95.  
MCAM is often expressed in endothelial-derived tumours such as haemangioma, 
angiosarcoma and Kaposi’s sarcoma 96. Finally, MCAM is expressed in a subset of leukemic cell 
lines and in some haematopoietic malignancies 97.  
The exact mechanism of MCAM overexpression in tumours is not yet known, however, 
it was shown that its expression is not due to mutations of the MCAM gene or chromosome 
translocations in melanoma 57. In prostate cancer, the MCAM promoter was found 
significantly hypermethylated when compared to the healthy prostate, and the amount of 
methylation correlated with the progression of the tumour 98. The possibility that MCAM is 
expressed due to environmental factors was further endorsed by the discovery that certain 
growth factors such as VEGF, as well as inflammatory cytokines (IFN-α) can promote MCAM 
expression 56,99.  
1.4.4. MCAM function 
There is much research into the function of MCAM protein showing its involvement in 
a broad range of cellular signalling pathways. Initially, it was thought that MCAM played a role 
as a cell adhesion molecule in malignant melanoma and was connected to melanoma 








tumour angiogenesis, cellular communication, cell-matrix interactions, transendothelial 
migration and immune responses 66.  
MCAM is involved in embryonic vessel development  
The involvement of MCAM in angiogenesis has been shown in early development. 
MCAM knock out impedes embryonic development of blood vessels in zebrafish 64, and blood 
vessels of kidney and retina in chicken 63,71. The mouse MCAM knock out develops normal 
blood vessels however, it has a negative effect on tumour angiogenesis in adult mice 100. 
Moreover, an antibody that inhibits angiogenic properties of MCAM diminished early vessel 
branching in the chicken chorioallantoic membrane (CAM) assay 101. 
MCAM in angiogenesis 
MCAM plays a role in many cell processes that are involved in angiogenesis, for 
example matrix degradation, loosening of cell junctions, proliferation, chemotaxis, migration 
and cell adhesion. In vitro assays on human endothelial cells showed that knock-down of 
MCAM by siRNA caused arrest in HUVEC proliferation, adhesion and migration 102. Antibodies 
against MCAM also inhibited HUVEC tube formation in vitro 101,103.  
Loosening of endothelial junctions and interaction with extracellular matrix 
The first step in angiogenesis is degradation of basal membrane and extracellular 
matrix protein complexes in order for endothelial cells to invade into the tissue 104. MCAM 
affects expression of several matrix metalloproteinases (MMP-2, MMP-9) 105,106, and targeting 
MCAM with an antibody AA98 inhibits tumour growth in xenograft mouse models due to 
impaired matrix degradation and invasion of blood vessels into the tumours 101. Furthermore, 
the endothelial cells in formed blood vessels need to loosen their connection, in order to start 








loosening of endothelial cell junctions and increases paracellular permeability as a co-receptor 
for VEGFR-2 100,107,108. MCAM antibody called P1H12 increased paracellular permeability of 
cultured human microvascular endothelial cells (HMVECs) 105. Increased permeability could 
also be caused by MCAM shedding form the cell membrane in response to selected 
environmental signalling, including VEGF and cellular calcium increase 69,99. Soluble MCAM 
further promotes endothelial cell proliferation. 
MCAM was found to increase cell migration on laminins. It was found that MCAM binds 
laminin 421 and 411 and facilitates cell migration in vitro 109. MCAM and laminin alpha 4 are 
highly expressed in several types of cancers possibly involved in tumour angiogenesis and 
tumour cell migration 110.  
Cell migration 
It has been shown that the neuronal guidance molecule netrin-1 has an effect on 
angiogenesis through its interactions with MCAM. Netrin-1 in low concentrations promotes 
angiogenic properties of HUVECs, such as proliferation, migration and network formation. It 
does so by binding MCAM and inducing dimerization, which then activates VEGFR-2, ERK1/2 
and p38 protein phosphorylation. However, this process is dependant on the amount of 
netrin-1 in the tissue, and a higher concentration (2000 ng/ml) activates UNC5B signalling and 
inhibits angiogenesis 111. MCAM can also activate migration by binding and initiating 
phosphorylation of ERM protein, which then activates RhoA-induced cytoskeleton 
reorganisation 112. Furthermore, MCAM knock down decreases the activity of RhoA 88. 
MCAM is also involved in regulation of cell polarity and migration by activating non-
canonical Wnt signalling. MCAM acts as a receptor for Wnt5a, activating downstream 








canonical signalling by promoting β-catenin degradation 113. Furthermore, MCAM causes 
cytoskeletal rearrangements by recruiting myosin and F-actin which cause cell membrane 
retraction in the direction of cell movement 114.  
Cell adhesion 
Cells expressing MCAM have increased self-adhesion 62 and MCAM is found expressed 
in the cellular junctions in cell-cell contacts of confluent cultured endothelial cells 107. MCAM 
crosslinking with S-Endo-1 promotes a signalling cascade by recruiting Fyn kinase (a Src family 
kinase) which then phosphorylates FAK and paxilin 115, proteins involved in forming focal 
adhesion plaques. Furthermore, MCAM expression increases as cells reach confluence 60, and 
it was reported that the phosphorylation of FAK and paxilin increases with cell density 116. 
MCAM is thus possibly involved in the connection between cells during formation of 
established blood vessels. Additionally, it was shown that balanced levels of VEGF are involved 
in maintenance of vessel integrity 16,117 and MCAM knock out impaired FAK phosphorylation 
in response to VEGF signalling 100. 
Soluble MCAM and tumour angiogenesis 
Soluble MCAM (sMCAM) has been found both in cultured HUVEC supernatants and in 
the blood of healthy individuals 68. However many reports indicate that sMCAM is increased 
in the plasma of cancer patients as well as in other conditions that involve endothelial 
disruption and inflammation 80,118–121. sMCAM binds Angiomotin isoform p80 (Amot p80) and 
induces pro-angiogenic effects on cultured endothelial cells as well as inducing angiogenesis 
in vivo in matrigel plug model and in mouse xenograft tumours 106. It is involved in promoting 








1.4.5. MCAM function in the immune system 
T-cells positive for MCAM expression secrete significantly more IL-17A, IL-6, and IL-8 
than MCAM negative cells 76,77. These cells show an effector memory phenotype and have a 
tendency to bind endothelium in order to extravasate into various tissues including crossing 
the blood brain barrier in certain neurodegenerative conditions 109,122. It is believed that 
MCAM facilitates this attachment to the blood vessels and facilitates extravasation by binding 
to either itself or another protein on endothelial cells. Certain immune modulating factors 
such as TNFα increase expression of MCAM on endothelial cells, as well as increase MCAM 
shedding by metalloproteinase 99. Shedding of MCAM from endothelial cells influences 
transmigration of immune cells by loosening endothelial cell junctions and inducing 
chemotaxis 99. This action can be blocked by antibodies against MCAM or by MCAM silencing 
via siRNA 99.  
Besides immune cells it was shown that MCAM knock out in mouse endothelial cells 
(isolated from MCAM knock out mice) significantly reduced transmigration of melanoma cells 
in response to VEGF signals, further confirming MCAM involvement in the endothelial barrier 
100. 
1.4.6. MCAM expression and function in renal cell carcinoma  
In healthy kidneys, MCAM is present in arteriolar endothelial cells (EC), mesangial cells 
and arteriolar smooth muscle cells 120. In chicken, MCAM is involved in kidney development 
and its expression is reduced in the adult tissue 63. However, MCAM is significantly 
upregulated in Wilms tumour (a form of kidney cancer) in adult chicken 71.  
The first paper indicating involvement of MCAM in human metastatic renal cell 








(insulin-like growth factor binding protein 4) had a 74-fold increase in MCAM mRNA, and an 
increase in MCAM protein level 123. They found that IGFBP-4 expression correlated with 
progression of RCC and activated Wnt signalling, which plays a role in progression of several 
cancers 124. IGFBP-4 affected proliferation, migration and invasion of transfected cells in vitro 
and increased cancer growth in a mouse model. They concluded that IGFBP-4 activates 
expression of MCAM in renal cell carcinoma and that both proteins could serve as potential 
prognostic markers for this cancer. Another group confirmed significant increase in MCAM 
expression in patients with progressed and metastatic RCC when compared to patients with 
localised disease 125. Additionally, they showed that MCAM expression correlated with higher 
risk of recurrence after partial or complete nephrectomy in patients that had no treatment 
prior to surgery. They showed this by analysing MCAM mRNA levels from the whole tumour 
tissue taken during the nephrectomy. Our group later identified MCAM expression in vessels 
of renal cell carcinoma, rather than in cancer cells, by immunohistochemistry 56. Here as well 
MCAM expression was connected to the poor patient prognosis. In the same study a 
monoclonal antibody towards mouse MCAM showed in vivo localisation to vessels in mouse 
RENCA tumour (a murine model of renal cell carcinoma), showing that targeting MCAM with 
monoclonal antibodies could be a possible new approach to treat advanced stages of RCC. 
Soluble MCAM is present in plasma of healthy donors, but is significantly increased in 
patients with chronic renal failure (CRF) 120. The same is true for MCAM expression in renal 
biopsies of CRF. MCAM is expressed on the cell junctions and CRF has been associated with 
endothelial cell junction changes 107. MCAM is possibly overexpressed and cleaved form the 








A study this year (2018) showed that soluble MCAM is increased in clear cell RCC in 
patients with higher risk of recurrence after initial sunitinib treatment 126. MCAM is a co-
receptor for VEGFR-2, a target of sunitinib, it is possible that an increase in MCAM expression 
and shedding could have an impact on bypassing anti-VEGF-targeted therapy. Thus, there may 
be benefit in dual targeting MCAM together with VEGF pathway to synergistically improve 
responses of clear cell RCC patients.  
1.4.7. Antibodies to MCAM protein 
Numerous antibodies against human MCAM have been developed over the years, with fairly 
diverse properties. For example, different antibodies pull down MCAM of different weight: 
113 kDa (MUC18, A32) 60,65, 118 kDa protein (S-Endo-1)73 or 110 kDa (mAb 541-30B2, 541-
1082 and 541-2E5) 127. Different immunohistochemistry staining patterns have been reported 
for different MCAM antibodies as well. MUC18 antibody stains only endothelial cells of 
capillaries and smooth muscle cells surrounding the vessels, while S-Endo-1 stains all the 
endothelial cells no matter the vessel size 65,73. Two monoclonal antibodies to MCAM (541-
1082 and 541-2E5) react with activated T cells, while no reaction to these cells was observed 
with MUC18 and A32 127. Antibody AA98 recognises MCAM expressed only on the tumour 
endothelium but does not recognise healthy vessels 101. In contrast, another antibody recently 
described against MCAM (TsCD146 mAb) stains only the tumour cells, without staining the 
blood vessels, while S-Endo-1 stains both the tumour cells and the blood vessels in the same 
tissue sample 128. It is assumed that this is due to the different glycosylation patterns, or 
available epitopes within different cells based on MCAM functions and environment in those 
cells 73,129. Lastly, antibody M2J-1 recognises only the soluble protein but not membrane 








The effects of antibodies on cell signalling and different MCAM pathways is also 
diverse. For example anti-human MCAM antibody ABX-MA1 blocks xenograft tumour growth 
and angiogenesis in mice 130, possible by decreasing expression of MMP-2 103, which is 
important in matrix degradation for blood vessel infiltration into the tumour tissue. Similarly 
it was found that antibody AA98 suppressed NF-kB activation and expression of MMP-9 and 
ICAM-1 and thus inhibits tumour angiogenesis 131. Furthermore, AA98 blocks in vitro HUVECs 
proliferation, while ABX-MA1 does not 101,103. In contrast, both antibodies inhibit capillary tube 
formation in a HUVECs angiogenesis assay. TsCD146 antibody which is specific to only tumour 








1.5 Aims and objectives 
We hypothesised that MCAM is a possible therapeutic target for vascular disruption 
and/or anti-angiogenic treatment in renal cell carcinoma. Therefore, we aimed to 
investigate MCAM as a possible therapeutic target in renal carcinoma mouse models 
(RENCA) by generating monoclonal antibodies targeting mMCAM. 
Next, we aimed to characterise the properties of anti-mMCAM antibodies for technical 
use as well as possible therapeutic utilisation. 
Lastly, in order to confirm whether MCAM has anti-angiogenic properties, we aimed 













Commonly used chemicals and reagents were purchased from Sigma Aldrich 
(Gillingham, UK), unless otherwise stated.  
 
Table 2.1 Buffers and solutions 
Buffer: Contents: 
PBS  Commercially available PBS tablets 
PBS-T PBS, 0.1% (v/v) Tween 20 
Ampicilin LB 100 µg/ml in LB agar or LB broth 
Kanamicin LB 50 µg/ml in LB agar or LB broth 
SDS-PAGE running buffer 25 mM Tris base, 250 mM glycine, 0.5% (v/v) SDS 
SDS-PAGE transfer buffer 25 mM Tris, 192 mM glycine, 20% (v/v) methanol  
Membrane blocking buffer PBS-T, 5% (w/v) dried skimmed milk (Marvel) 
ELISA blocking buffer PBS, 2% (w/v) dried skimmed milk 
Tris-acetate-EDTA (TAE) 
buffer 
40 mM Tris, 20 mM acetic acid, 1 mM EDTA 
Flow cytometry buffer PBS, 0.2% (w/v) BSA, 0.02% (v/v) sodium azide  
Papain cleavage buffer 150 mM NaCl, 0.67 mM EDTA, 5 mM L-cysteine, 10 mM 
NaH2PO4 
Oligo annealing buffer 10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA 
Beads wash buffer PBS, 287 mM NaCl, 0.1% (v/v) NP-40 
Non-reducing protein loading 
buffer 
50 mM Tris HCl pH 6.8, 10% (v/v) glycerol, 2% (v/v) SDS, 
0.001% (w/v) bromophenol blue 
Reducing protein loading 
buffer 
Non-reducing protein loading buffer, 1.25% (v/v) 
β-mercaptoethanol 
NP-40 lysis buffer 50 mM Tris pH 7, 1% (v/v) NP-40, 150 mM NaCl, 1 mM 












Table 2.2 List of antibodies and dilutions used for given applications: WB – Western blot, FC – flow 
cytometry, IF – immunofluorescence, IHC – immunohistochemistry, ELISA – enzyme-linked 
immunosorbent assay, IP – immunoprecipitation  
Specificity Species Application 
dilution 
Reference number Source 
Human MCAM Rabbit WB 1:1000 
ELISA 1 µg/ml 
HPA008848 Sigma  
Mouse MCAM Sheep WB 1:500 
ELISA 1 µg/ml 
AF6106 R&D (Minneapolis, 
US) 
Mouse MCAM Rat 
monoclonal 
WB 1:500 
FC 10 µg/ml 




His tag  Mouse 
monoclonal 
WB 1:1000 
ELISA 1 µg/ml 
MAB050 R&D 
FLAG tag Mouse 
monoclonal 
WB 1:1000 ab49763 (M2) Abcam (Cambridge, 
UK) 
Human Tubulin Rabbit WB 1:1000 2144S  Cell Signalling 
Technology 
(Danvers, USA) 
Human CD31 Mouse 
monoclonal 
IF 1:200 550389 (WM59) BD Biosciences 
(Oxford, UK) 
Human IgG-HRP Goat WB 1:1000 
ELISA 1 µg/ml 
A0170 Sigma 
Rabbit IgG-HRP Goat  WB 1:5000 
ELISA 1:2000 
7074S Cell signalling 
Sheep IgG-HRP Donkey WB 1:5000 
ELISA 1:2000 
HAF016 R&D 
Rat IgG-HRP Rabbit  WB 1:5000 
IHC 1:100 
ELISA 1:2000 
P0450 DAKO (Cambridge, 
UK) 





Goat IF 1:200 
FC 1:100 




Gaot IF 1:200 A21247 Invitrogen 
AlexaFluor® 488 
anti-rat IgG 





Table 2.3 List of control species IgG 







Rat IgG 2mg/ml IHC 10/15 µg/ml 
IF 10 µg/ml 
FC 10 µg/ml 










2.2 Molecular cloning  
Table 2.4 List of gene DNA templates 
Reference number cDNA Source 
MHS 6278-202760082 Human MCAM Provided by Victoria Heath 
MMM 1013-202770023 Mouse MCAM Provided by Victoria Heath 
 
Table 2.5 List of oligonucleotides 
Oligo lable  Name  Sequence 5’ – 3’ 
VH517 mMCAM EcoRI forward TAGTAGGAATTCGGAAGCATGGGGCTGCCCAAAC 
VH518 mMCAM NotI reverse CTACTAGCGGCCGCCACCTTTGCTCTCTGGCTGTGG 
VH519 hMCAM EcoRI forward TAGTAGGAATCCGGAAGCATGGGGCTTCCCAGG 
VH520 hMCAM NotI reverse CTACTAGCGGCCGCCGCCCCGGCTCTCCGGCTCCGG 
MC08 His NotI forward GGCCGCCATCATCACCATCACCACTAGT 
MC09 His XbaI reverse CTAGACTAGTGGTGATGGTGATGATGGC 
MC12 hMCAMseq701 forward GGAACCACATGAAGGAGTCC 
MC13 hMCAMseq1295 forward CCCCTTGGATGGCATTCAAG 
MC14 mMCAMseq654 forward GGAAGACAAAGATGCCCAGT 
MC15 mMCAMseq1254 forward TCCTGGCTTGAATCGTACCC 
MC24 mMCAM FL-FLAG reverse1 
CTACTTGTCATCGTCATCCTTGTAATCACTCGATGAAG
AATGCCTCAGATCGATG 
MC25 mMCAM FL-FLAG forward CGAGACTAGCCTCGAGGTTTAAACGGAAGCATGGGGCTGCCC 
MC26 mMCAM FL-FLAG reverse2 
ATTCCTGCAGCCCGTAGTTTAAACCTACTTGTCATCGT
CATCCTTGTAATCACTC 
MC30 mMCAMdel1 NotI reverse TAGTAGGCGGCCGCCTGCCATCCATGGGGACCC 
MC31 mMCAMdel2 NotI reverse TAGTAGGCGGCCGCCCAGCAGCTCCAGGGGGTC 
MC32 mMCAMdel3 NotI reverse TAGTAGGCGGCCGCCTGCAGGGTAGAAAACAG 
CMV fwd CMV promotor forward CGCAAATGGGCGGTAGGCGTG 
EF-1a fwd EF-1a promotor forward TCAAGCCTCAGACAGTGGTTC 
IRES rev 5' end of IRES reverse  CCTCACATTGCCAAAAGACG 
EGFP-N rev 5' end of EGFP reverse CGTCGCCGTCCAGCTCGACCAG 
 








Table 2.6 List of cloned DNA plasmid constructs 
Construct Vector  Restriction site PCR primers Ligation  









































F – forward primer, R – reverse primer, T4 – T4 DNA ligase reaction, GA – Gibson Assembly reaction 
 
2.2.1. Agarose gel electrophoresis and DNA visualization 
Agarose gel electrophoresis was used for the separation, size estimation and 
visualization of DNA. Agarose gels were prepared from 0.7% - 2% (w/v) agarose powder in 
Tris-acetate-EDTA (TAE) buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA), with addition of 
SYBR™ Safe DNA Gel Stain (Invitrogen, Paisley, UK). DNA was mixed with 6x DNA loading buffer 
(Thermo Scientific, Walmington, UK) and loaded to gels immersed in TAE buffer. 
Electrophoresis was carried out in electrophoresis tanks at 100 - 120 V for 20 - 40 minutes 
(min), depending on the size of the DNA and percentage of agarose gels. DNA size markers 
were used to distinguish the DNA base pare (bp) length: GeneRuler 1 kb DNA Ladder, 
GeneRuler 100 bp DNA Ladder (both Thermo Scientific). DNA was visualised and analysed 









2.2.2. DNA isolation and purification 
DNA was purified from polymerase chain reaction (PCR) mix using a QIAquick PCR 
Purification Kit (Qiagen, Manchester, UK) following manufacturer’s instructions. DNA was 
extracted and purified from agarose gels using a QIAquick Gel Extraction Kit (Qiagen). Plasmid 
DNA was isolated from bacterial lysates using a QIAprep Spin Miniprep Kit (Qiagen) or a 
NucleoBond® Xtra Midi (Fisher Scientific, Loughborough, UK) plasmid DNA purification kit. For 
all isolations, DNA was eluted in the elution buffer provided by the manufacturer and the DNA 
concentration was determined by a NanoDropä1000 spectrophotometer (Thermo Scientific).  
2.2.3. DNA amplification  
2.2.3.1 Polymerase chain reaction (PCR) 
DNA fragments were amplified by PCR with specific primers (listed in Table 2.5 and Table 2.6) using 
Q5® High-Fidelity DNA Polymerase (New England Biolabs, Herts, UK) following the manufacturer’s 
instructions and summarised in Table 2.7 and  
 
Table 2.8. The initial denaturation step was prolonged to 5 min when the DNA was 
amplified from bacterial cells. The annealing temperature was adjusted based on the Tm 
(melting temperature) of primers and the elongation time was adjusted to the length of the 
DNA construct. 
Table 2.7 PCR reaction reagents 
Reagent  Concentration 
5X Q5 Reaction Buffer 1X 
10 mM dNTPs 200 µM 
10 µM Forward Primer 0.5 µM 
10 µM Reverse Primer 0.5 µM 
Template DNA < 1,000 ng 
Q5 High-Fidelity DNA 
Polymerase 
0.02 U/µl 
5X Q5 High GC Enhancer 1X 










Table 2.8 PCR reaction conditions 
Step Temp Time Cycles 
















2.2.3.2 Plasmid DNA amplification 
Plasmid DNA was amplified in bacteria. A single colony was taken from a selective LB 
(Luria Bertani) agar plate and incubated overnight in 5 ml (miniprep) or 250 ml (midiprep) of 
fresh LB broth medium with the appropriate antibiotic selection, at 37 °C in a shaking 
incubator at 200 rpm. The overnight bacterial culture was pelleted and used for plasmid DNA 
purification in mini- or midipreps as described in 2.2.2. 
2.2.4. Restriction digests  
Restriction digests were carried out in 20 - 50 µl volumes, using 1 - 5 µg of DNA 
following manufacturer’s recommendations for each enzyme. When possible, double 
digestion using two enzymes, was carried out in the most suitable buffer. Restriction enzymes 
EcoRI, NotI, XbaI and PmeI were from New England Biolabs (NEB). The cut DNA fragments 
were separated by agarose gel electrophoresis and purified as per section 2.2.2. 
2.2.5. T4 DNA ligase reaction 
Plasmid vectors and PCR products, cut with complementary restriction enzymes, were 








as recommended by the manufacturer. The reaction was carried out at room temperature for 
5 h or overnight. The reaction was directly transformed into bacterial cells. 
2.2.6. Annealing of His tag oligonucleotides and cloning of His-tagged MCAM proteins 
The sense and antisense 6xHis tag oligonucleotides (oligos) (MC08 and MC09) were 
annealed to form the 6xHis tag DNA insert. Briefly, 2 µg of each oligo was mixed together in 
50 μl of annealing buffer (10 mM Tris pH 7.5, 50 mM NaCl, 1 mM EDTA). This was incubated 
at 92.5 °C for 5 min. The reaction was then slowly cooled to room temperature for 1 h. 
Annealed oligos were diluted 10 times in nuclease free water, and the concentration was 
checked by a NanoDropä. This tag was used in construction of the m/hMCAMecd-His 
constructs. The human Fc sequence was excised from the m/hMCAMecd-Fc plasmids using 
NotI and XbaI restriction enzymes and the 6xHis tag was cloned in to replace the Fc tag in a 
ligation reaction with T4 DNA ligase, generating m/hMCAMecd-His constructs.  
2.2.7. Gibson assembly and cloning of FLAG-tagged full length mouse MCAM 
Primers for Gibson cloning were designed using the online NEB builder tool 
(http://nebuilder.neb.com). Constructs were designed to conserve the restriction sites 
flanking the inserted DNA. The FLAG tag was added at the C-terminus of the mouse MCAM 
full length in a PCR reaction using primers MC24 and MC25. This PCR product was then used 
as a template for the second PCR reaction using Gibson Assembly designed primers (MC25 
and MC26). pWPI plasmid was cut with PmeI restriction enzyme, as described in 2.2.4. The 
second PCR product and the cut plasmid were mixed in a 3:1 ratio with 2X Gibson Assembly 
Master Mix (NEB) according to the manufacturer’s instructions and incubated for 30 min at 








2.2.8. Transformation of chemically competent E. coli  
Plasmid DNA solution (2 μl of a ligation or Gibson Assembly) was added to chemically 
competent E. coli (α-Select Gold Efficiency, Bioline, London, UK) and mixed gently. Cells were 
incubated on ice for 20 min, heat-shocked at 42 °C for 90 seconds (sec) and immediately 
transferred to ice. Room temperature LB broth medium without antibiotics was added to the 
bacterial cells before shaking horizontally (200 rpm) at 37 °C for 1 h. After shaking, bacterial 
cells were spread on the pre-warmed LB agar plates containing appropriate antibiotic and 
incubated overnight at 37 °C. Five to ten colonies were picked the following day and analysed 
for transformation efficiency using direct PCR from bacteria (colony PCR). Positive colonies 
were cultured overnight in 5 ml of LB broth medium with antibiotics, the plasmids purified 
and digested with restriction enzymes flanking the insert. Finally, plasmids with the predicted 
digestion pattern were sequenced.  
2.2.9. DNA sequence analysis 
Plasmid DNA was purified as described in section 2.2.2 and the concentration was 
determined by a NanoDropä. Approximately 500 ng of DNA was mixed with 1 μl of 3 µM 
sequencing primer in a reaction volume of 10 μl. The samples were processed by University 
of Birmingham DNA sequencing services and run on the capillary sequencer ABI 3730 for 
sanger sequencing. The correct nucleotide sequence and amino acid reading frame of 









2.3 Cell culture 
Table 2.9 Cell culture media and solutions 
Cell type Medium name and supplements  Concentration of supplements 
HUVEC (isolated in the 
lab) 
Complete M199 (Sigma Aldrich) 
FCS (Thermo Scientific) 
L-glutamine (Gibco, Paisley, UK ) 
Penicillin (Gibco) 
Streptomycin (Gibco) 
Heparin (LKT Laboratories, 
Ontario, Canada) 















Amphotericin B (Gibco) 
Heparin 




















Commercial HUVEC Complete EBM2 (Lonza clonetics) 
EBM®-2 Bulletkit (Lonza clonetics) 
 
1X 






























Rat hybridoma cells  Hybridoma DMEM 
FCS 
L-glutamine 








































HDF Complete M106 (Gibco) 
LSGS (Life Tech) 
 
1X  
   
2.3.1. General cell culture and passaging 
All procedures were carried out in sterile conditions in a Class II, Type A2 biological 
safety cabinet (Holten Laminar Air). Cell culture plates for Human Umbilical Vein Endothelial 
Cells (HUVECs), Human Dermal Fibroblast (HDF) cells and Mouse Brain Endothelial (bEND) cells 
were coated with 0.1% (w/v) gelatin (Fluka BioChemika) in PBS before cell seeding. Different 
mammalian cell types were grown in cell culture media (listed in Table 2.9) as stated in the 
different methods sections. Cells were cultured in a humidified cell culture incubator (Sanyo 
CO2 incubator, Osaka, Japan) at 37 °C and 5% CO2.  
Cells were grown until 80 - 90% confluent, washed 2 times with sterile PBS and 
detached from plates using vigorous pipetting (HEK, RENCA, hybridomas), 0.1% (v/v) Trypsin-
EDTA (Gibco) in PBS (HUVEC, bEND, sEND, HDF), or non-enzymatic cell dissociation solution 
(Sigma) (when used for flow cytometry). Cells were washed from dissociation solutions with 
complete medium (specific for each cell type, Table 2.9), spun down at 196 x g for 5 min and 








in a ratio of 1:3; bEND, sEND and HDF cells were split in a ratio of 1:5; HEK293T and RENCA 
cells were split in a ration of 1:10.  
2.3.2. Human umbilical vein endothelial cells preparation  
Umbilical cords were obtained from the Birmingham Women’s Hospital, with mothers’ 
consent by members of the Birmingham Biorepository. Cords were cannulated, and the vein 
washed 2 times with PBS to remove blood. The vein was filled with collagenase type 1A (1 
mg/ml) in M199 medium and incubated at 37 °C for 20 min to dissociate the endothelial cells 
from the cord. Cells were flushed through the cord with PBS into a 50 ml centrifuge tube, 
washed 2 times with PBS to remove the collagenase and seeded onto gelatin coated tissue 
culture flasks in low passage M199 medium (Table 2.9). The medium was changed 4 hours (h) 
later, and the cells cultured until confluent. HUVECs were used from passage 2 to 6. 
2.3.3. Mammalian cell storage 
Cells were washed with PBS and detached from plates as described in 2.3.1. Spun-
down cells were resuspended in freezing medium [10% (v/v) DMSO in FCS] and stored in Mr. 
Frosty™ freezing container at -80 °C overnight. Cells were then transferred to liquid nitrogen 
for long-term storage. For reseeding, frozen cells were rapidly thawed in a 37 °C water bath, 
washed with their respective medium, spun down at 196 x g for 5 min, and plated in the 
complete medium. 
2.3.4. Mammalian cell lysis 
Cells in the culture dishes were washed 2 times with non-sterile PBS on ice. NP-40 lysis 
buffer [50 mM Tris pH7, 1% (v/v) NP-40, 150 mM NaCl, 1 mM EDTA, protease inhibitors, 








Cells were scraped and collected into a microcentrifuge tube, vortexed for 20 sec and 
incubated on ice for 15 min. Cell debris was pelleted by centrifugation at 16602 x g for 15 min 








2.4 Mammalian cell DNA transfection and transduction 
2.4.1. HEK293T cell transient DNA transfection using PEI 
Table 2.10 shows the conditions for cell transfections related to the size of the culture 
plates. HEK293T cells were seeded at an appropriate density in complete DMEM (10% FCS). 
On the following day, the plasmid DNA was mixed with 1 mg/ml polyethylenimine (PEI) as 
indicated in Table 2.10 in Opti-MEM, gently vortexed and incubated for 10 min at room 
temperature. The DNA-PEI mix was added drop-wise to the cells. Transfected cells, or cultured 
medium, were analysed two or more days after transfection.  
Table 2.10 PEI transfection reagents for different sizes of cell cultures 
Plate size Medium volume Cells seeded Opti-MEM DNA PEI 
6-well 2 ml 3x105 100 µl 1 µg 4 µl 
6 cm 3 ml 1x106 300 µl 3 µg 12 µl 
10 cm 10 ml 3x106 1 ml  9 µg 36 µl 
15 cm 20 ml 6x106 2 ml  18 µg 72 µl 
 
2.4.2. Production of lentivirus in the cell culture medium of HEK293T cells 
HEK293T cells were seeded in complete DMEM the day before PEI transfection; 3x106 
cells per 10 cm cell culture plate. The cells were transfected with 36 µl of PEI and a mix of 
plasmids: 
1) 4.4 µg of lentivirus vector 
2) 3.3 µg of packaging vector (PsPAX2)  
3) 1.3 µg of envelope vector (PMD2G), 
as described in section 2.4.1. The cells were left to generate and secrete the virus into 
the supernatant. Cell supernatant containing lentivirus was collected after 48 h and filtered 








2.4.3. Lentiviral transduction of HEK293T cells 
Sterile polybrene was added to lentivirus medium to a final concentration of 8 µg/ml. 
Media was then added to the HEK293T cells seeded (3x106) a day previously in a 10 cm plate. 
Cells were cultured in lentivirus medium for 24 h before the medium was replaced with 
complete DMEM. Cells were analysed for transduction efficiency two days later using 
fluorescence imaging (EVOS® fl, Thermo Fisher) by checking the expression of green 
fluorescent protein (GFP) expressed from the pWPI vector. 
2.4.4. Lentiviral transduction of HUVECs for angiogenesis assays 
HEK293T cells were PEI transfected, as described previously (2.4.2), with GFP 
expressing plasmid and a mix of plasmids encoding lentiviral proteins. Lentivirus-containing 
medium was collected after two days, filtered through a 0.45 µm syringe filter and stored at -
80 °C. HUVECs were seeded the day before transduction (2.5x105) in a T25 tissue culture flask. 
Polybrene was added to the lentivirus medium to a final concentration of 8 µg/ml. This 
medium was added to the HUVECs for transduction. After 24 h, the medium was replaced with 








2.5 Protein expression in mammalian cells and affinity purification  
2.5.1. Small scale protein production and affinity pull-down 
HEK293T cells were transiently transfected with plasmids containing recombinant 
protein expression construct (as described in 2.4.1) and cultured for 48 h in complete DMEM, 
after which the medium was changed to serum free OptiMEM. The Opti-MEM was sampled 
(1 ml) after two days, sterilised through a 0.22 µm syringe filter and incubated with 20 μl of 
protein A (Sigma) or Ni-NTA sepharose bead slurry (Sigma) overnight at 4 °C with rotation. 
Beads were washed 3 times with 1 ml of beads wash buffer followed by boiling at 95 °C for 5 
min in reducing protein loading buffer. Binding of proteins to the beads was visualised using 
SDS-PAGE and Coomassie blue staining of the gels.  
2.5.2. Large scale protein production 
HEK293T cells were transiently transfected with plasmids containing recombinant 
protein construct and expanded to 10 x 15 cm tissue culture plates in complete DMEM. After 
reaching confluence, the medium was replaced by serum free Opti-MEM. The Opti-MEM 
containing recombinant protein was then collected twice a week for two weeks and sterile 
filtered through a 0.22 µm filter with addition of 0.5 mM EDTA and a small amount of PMSF 
crystals (for protease inhibition). In His-tagged protein containing medium only PMSF crystals 










2.5.3. Purification of Fc-tagged proteins on a Protein A column 
All buffers and media were sterile filtered through a 0.22 μm filter prior to use. 
HiTrap™ Protein A HP column (GE healthcare, Amersham, UK) was assembled on a pump 
system (Miniplus 2, GILSON) at 4 °C. The column was then washed with five column volumes 
of dH2O, followed by five volumes of 20 mM sodium phosphate buffer (pH 7) to equilibrate 
the column. Medium containing mMCAMecd-Fc/hMCAMecd-Fc protein was run through the 
column at a speed of less than 1 ml per minute. The column was then washed with five 
volumes of 20 mM sodium phosphate (pH 7) and proteins eluted with 100 mM Sodium Citrate 
(pH 3) in around 20 fractions of 0.5 ml to complete protein elution. The pH of eluted fractions 
was adjusted to pH 7 by addition of 1 M Tris (pH 9). Fractions with the highest concentration 
of protein (measured on a NanoDropä) were pooled together and dialysed against PBS, sterile 
filtered through a 0.22 μm filter and stored at 4 °C.  
After elution, the column was washed with five volumes of 20 mM sodium phosphate 
buffer (pH 7), followed by five volumes of dH2O and then five volumes of 20% (v/v) ethanol, 
in which the column was stored.  
2.5.4. Purification of His-tagged proteins on a Ni-NTA column 
A HisTrap™ Excel column (GE healthcare) was assembled on a pump system at 4 °C, 
washed with five column volumes of dH2O, followed by five volumes of PBS, and then five 
volumes of PBS, 0.5 M NaCl. After that, the medium containing mMCAMecd-His/hMCAMecd-
His protein was run through the column at a speed of less than 1 ml per minute. The column 
was washed with five volumes of PBS, 0.5 M NaCl and the proteins were eluted in elution 
buffer (PBS, 0.5 M NaCl, 250 mM imidazole) in 0.5 ml fractions. The elution buffer was left to 








This step was repeated until no protein could be detected in the elution fractions. Protein 
concentration was checked by a NanoDropä. Collected elution fractions were pooled 
together and dialysed against PBS, sterile filtered through a 0.22 μm filter and stored at 4 °C. 
The column was washed with five volumes of PBS, 0.5 M NaCl, followed by five volumes of 
PBS and five volumes of dH2O. Finally, the column was flushed with 20% (v/v) ethanol and 
stored for later use. 
2.5.5. Papain cleavage and depletion of the Fc tag 
2.5.5.1 Optimization of enzyme digest 
30 µg of Fc-tagged protein was incubated at 37 °C in 100 µl of papain cleavage buffer 
(150 mM NaCl, 0.67 mM EDTA, 5 mM L-cysteine, 10 mM NaH2PO4). Before the addition of 0.8 
µl of 0.2 mg/ml of papain, 10 µl of this reaction was sampled. After the addition of papain, an 
additional 10 µl of reaction was taken at 5, 10, 20, 30, 40, 50 and 60 min and the reaction was 
stopped by addition of reducing protein loading buffer and boiling at 95 °C for 5 min. The 
proteins were separated by SDS-PAGE and analysed by Coomassie blue staining.  
2.5.5.2 Large scale papain digest 
Larger amounts of protein were papain cleaved in 1 ml of papain cleavage buffer 
containing 1.6 µg/ml papain. The reaction was carried out for 30 min at 37 °C and was stopped 
by the addition of 6.5 mM (final concentration) iodoacetic acid (pH 6.8) for 30 min at room 
temperature. The cleaved Fc fragment was depleted from the solution using Protein A beads. 
Before use, the protein A beads were washed 3 times with beads wash buffer and 50 µl of 
beads were added to the protein solution. The solution was incubated with beads for 2 h at 4 








fresh beads twice more. Absence of the Fc tag in the depleted solution was confirmed using 









2.6 SDS-PAGE and Western blot 
Table 2.11 SDS-PAGE gel contents 
Buffer: Contents: 
10% resolving gel 375 mM Tris pH 8.8 
0.1% (v/v) SDS 
10% (w/v) Acrylamide; 0.26% (w/v) Bis-Acryl-amide 
0.1% (w/v) ammonium persulphate (APS) 
0.1% (v/v) TEMED 
Stacking SDS gel 125 mM Tris pH 6.8 
0.1% (v/v) SDS 
5% (w/v) Acrylamide; 0.13% (w/v) Bis-Acryl-amide 
0.1% (w/v) APS 
0.1% (v/v) TEMED 
 
Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) was used 
to separate and visualise proteins. Gels consisted of a 10% resolving gel at the bottom and a 
stacking gel at the top (Table 2.11). Proteins were loaded in protein loading buffer (reducing 
or non-reducing) to the stacking gel. Electrophoresis was carried out in SDS running buffer at 
80 V while proteins went through the stacking gel, and 120 V through the resolving gel; in a 
gel electrophoresis tank XCell SureLock™ Electrophoresis (Invitrogen). Proteins were 
subsequently stained in the gel with InstantBlue™ protein gel staining solution (Expedeon) as 
recommended by the manufacturer (referred to as Coomassie blue later in text) or transferred 
to Immobilon®-P PVDF membrane (Merck-Millipore, Darmstadt, Germany).  
Prior to transfer, the membrane was activated with methanol and rinsed with water 
and then transfer buffer. The membrane and gel were assembled as a sandwich between 
blotting paper and sponges immersed in the transfer buffer in an XCell II™ Blot Module 
(Invitrogen). The transfer was carried out at 4 °C, 30 V and 400 mA for 2 h. The membrane was 
then incubated in blocking buffer [5% (w/v) dried skimmed milk, PBS-T] at room temperature 








BSA, PBS-T (concentrations specified in Table 2.2 for each antibody) for 1 h at room 
temperature or overnight at 4 °C. Membranes were washed 4 times for 5 min with PBS-T, and 
probed with species specific secondary antibody conjugated to HRP (1:5000) in blocking 
buffer. Membranes were then washed 4 times for 5 min with PBS-T. The membranes were 
incubated with Amersham™ ECL™ Western Blotting Detection Reagents and placed in a 
developing cassette (Hypercassette™, Amersham Biosciences) together with the film 









2.7 The enzyme-linked immunosorbent assay (ELISA) 
 C96 MaxiSorp Nunc-Immuno Plates (Thermo Scientific) were coated overnight with an 
appropriate amount of protein (20-500 ng/well) with agitation at 4 °C. Wells were then 
washed 3 times with 200 μl PBS, before blocking with 300 μl of PBS, 2% (w/v) milk powder 
(Marvel) for 2 h at room temperature. Wells were then washed again 3 times with 200 μl of 
PBS. Proteins were then probed with antigen-specific antibodies (100 μl, concentration of 1 
μg/ml), diluted animal serum (100 μl), undiluted cell supernatants (100 μl) or PBS without 
antibody for 1 h at room temperature. Unbound antibody solutions were washed 3 times with 
PBS-T and 3 times with PBS before probing with 100 μl of species-specific secondary antibody 
conjugated to HRP (1:2000 dilution in PBS) for 1 h at room temperature. Wells were again 
washed 3 times with PBS-T and 3 times with PBS. Reaction was initiated by addition of 50 μl 
of HRP substrate solution BM Blue POD Substrate (Roche) and incubation for 10-30 min before 
stopping the reaction with 30 μl of 3 M HCl. Absorbance was recorded on VersaMax™ ELISA 









2.8 Antibody generation 
2.8.1. Mouse immunisations 
2.8.1.1 Mouse immunisation carried out by Eurogentec S.A. 
Eurogentec S.A. carried out mice immunisation and splenocyte fusion. Six mice were 
immunised with mMCAMecd-Fc (50 µg) 4 times with two weeks between immunisations. The 
first immunisation was with Freund’s complete adjuvant (FCA) while the rest were with 
Freund’s incomplete adjuvant (FIA). Bleeds were taken from mice prior to the first 
immunisation and one week after the last one and tested on ELISA. A positive mouse was 
culled for fusion. Mouse splenocytes were fused with mouse myeloma cell line (Sp2/OAg 14) 
to generate the hybridoma cells. Pools of hybridoma cells were cultured and the supernatants 
of different pools tested on ELISA for reactive antibodies.  
2.8.1.2 Mouse immunisation carried out at University of Birmingham 
This work was carried out under the home office license number 70/8704. Three 6-
week-old male Balb/c mice were first immunized the first time with a mix of antigen (50 µg) 
and Freund’s complete adjuvant subcutaneously. Subsequently, mice were injected 
subcutaneously every two weeks with 50 µg of antigen and Freund’s incomplete adjuvant. 
Bleeds from saphenous veins were taken prior to the first immunisation and 13 days after 
each immunisation to assess the antibody titre in the serum. After four immunisations, the 
mice with the highest titre were boosted with a final injection of 10 µg of antigen in PBS 
intraperitoneally and culled 3 days later. The spleen was taken for the immediate isolation of 








2.8.2. Rat immunisations carried out by Biogenes GmbH 
Three Dark Agouti rats (female, 8 weeks old) were immunised intraperitoneally 4 times 
over a period of 39 days. Rats were immunised with water-in-oil emulsion that was prepared 
by emulsifying the 50 µg of antigen in equal volumes of Freund’s complete adjuvant (first 
immunisation) and Freund’s incomplete adjuvant (subsequent boosts). Bleeds were taken one 
week after the 3rd immunisation and tested on ELISA with m/hMCAMecd-His protein. Two rats 
were boosted 20 days after the last immunisation and culled for fusions 3 days later. Spleens 
were pooled and homogenized and the cells fused to mouse myeloma Sp2/0-Ag14 cells. The 
hybridoma cells were plated on the pre-coated peritoneal exudate cells as feeder cells in 
complete cell growth medium supplemented with 20 % FCS, antibiotic/antimycotic (final 
concentrations: 100 U/ml Penicillin G, 250 ng/ml Amphotericin B, and 100 μg/ml 
Streptomycin) and HAT supplement (100 μM hypoxanthine, 400 nM aminopterin and 16 μM 
thymidine). The supernatants of individual hybridoma clones were tested on ELISA. The third 
rat was immunised again after around four months of waiting period. This rat was then culled 
3 days later. The spleens were taken immediately and splenocytes fused as described for the 
other two rats. 
Positive hybridoma cells were then sub-cloned by limiting dilution. Wells with single 
cell colonies were regarded as monoclonal cell lines and tested for mMCAMecd-His 
recognition. These cells were then again sub-cloned in the same way, and only wells 
containing a single clone were selected for further processing. Cells from positive wells were 
passaged several times to identify the best clones with regard to cell growth and antigen 








2.8.3. Hybridoma cell fusion carried out within University of Birmingham 
The isolated spleen was punctured with a syringe to create small holes through which 
the cells were flushed with RPMI medium into the petri dish. Cells and spleen were then gently 
pushed through a 40 µm Blue filter (BD) to create a single cell suspension. Cells were washed 
3 times with RPMI without serum and counted. Myeloma cells (NSO) were collected from 
plates, washed and counted. Myeloma cells and spleen cells were mixed together (in a ratio 
of 1:5) in a tube with a spherical bottom. Cells were spun down and the medium aspirated 
leaving the pellet as dry as possible. 1 ml of PEG (50% v/v) was added slowly, over 1 minute, 
to the cells with a plastic Pasteur while stirring the cells gently with the Pasteur. After this, 20 
ml of warm RPMI was added in the same manner as the PEG, 1 ml per minute gently while 
stirring the cells. Cells were left in this solution for 5 min without disturbance. Another 30 ml 
of RPMI was then added in the same way but a bit faster. Cells were then spun down at 468 x 
g for 7 min and the supernatant removed. Cells were resuspended in 50 ml of RPMI containing 
20 % (v/v) FCS. Cells were counted and the amount of 96 well plates needed for seeding 1 cell 
per well was calculated. Cells were diluted in 15 % (v/v) FCS RPMI and seeded in 96 well plates 
at 150 µl/well. On the following day, 150 µl/well of RPMI containing 15 % (v/v) FCS and 2X 
HAT was added to the cells in addition to the antecedent medium. 10 days later the plates 
were screened for growing colonies in each well. The media from wells with colonies were 
collected and screened on ELISA. 
2.8.4. Isotype determination 
The monoclonal antibody isotype was determined with Ig Isotyping Rat Uncoated 
ELISA Kit (Invitrogen). The antibodies were tested for IgG1, IgG2a, IgG2b, IgG2c, Kappa and 








wells of an ELISA plate overnight. This was aspirated, and the wells washed 2 times with wash 
buffer [PBS, 0.05% (v/v) Tween 20] and blocked with 250 µl of blocking buffer [PBS, 0.1% (v/v) 
Tween 20, 1% (w/v) BSA] for 3 h at room temperature. The hybridoma supernatants were 
diluted 2 times in PBS and 50 µl of diluted supernatants were mixed with 50 µl of assay buffer 
[PBS, 0.05% (v/v) Tween 20, 0.05% (w/v) BSA]. Blocking buffer was washed from the wells and 
the wells incubated with supernatants and controls for 2 h at room temperature. This was 
washed 4 times with wash buffer, then 100 µl of detection antibody diluted in the assay buffer 
was added and incubated for 1 h at room temperature. This was again washed 4 times and 
the substrate solution, Tetramethylbenzidine, TMB, added and incubated for 15 min at room 
temperature. Finally, the stop solution (3 M HCl) was added and the absorbance at 450 nm 
read with a plate reader.  
2.8.5. Antibody purification 
Small scale rat monoclonal antibody purification from hybridoma supernatants was 
performed by incubation of 10 ml of supernatants with 300 μl of protein A beads overnight at 
4 °C with agitation. Beads were washed 3 times with 5 ml of beads wash buffer. Antibodies 
were eluted with 100 mM Sodium Citrate (pH 3), and pH set to neutral (pH7) with 1 M Tris (pH 
9). The concentration was checked by a NanoDropä. Margaret Goodall, University of 
Birmingham, purified monoclonal antibodies on a large scale using a protein G column. 
2.8.6. Antibody labelling 
Purified rat monoclonal antibody mMCAM10 against mMCAMecd was fluorescently 









2.9 Flow cytometry 
2.9.1. Flow cytometry for antibody validation 
HEK293 and bEND cells were detached from plates using non-enzymatic cell 
dissociation solution (Sigma), collected into cell culture medium (specific for each cell type 
listed in Table 2.9) and centrifuged at 196 x g for 5 min (same speed and time used in all the 
centrifugation steps in this protocol). The cells were then resuspended in flow cytometry 
buffer [PBS, 0.5% (v/v) FCS, 2 mM EDTA] and separated into Eppendorf tubes in equal amounts 
for the different samples (at least 100,000 cells per sample). Cells were centrifuged and 
resuspended in 50 µl of antibody solution, isotype control, hybridoma supernatants or empty 
flow cytometry buffer and incubated for 1 h on ice. The primary antibody and a species-
matched non-specific IgG were diluted in flow cytometry buffer to a final concentration of 10 
µg/ml. Undiluted tissue culture supernatants from rat hybridoma clones were used. Following 
incubation, cells were washed with 300 µl of flow cytometry buffer and spun down. Cells were 
resuspended in the buffer with fluorescently labelled species-specific secondary antibody 
(1:100) and incubated in the dark for 1 h on ice. 300 µl of buffer was added to the cells before 
analysis by a CyAn ADP flow cytometer (Beckman Coulter), using Summit software. Gates were 
set with the control cells incubated with flow cytometry buffer only for single cells (singlets), 
and cells incubated with control IgG and secondary were used to set the gates for specific 









2.9.2. Antibody competition assay 
bEND cells were prepared as in 2.9.1 then incubated with 50 µl of blocking antibody at 
a concentration of 100 µg/ml in flow cytometry buffer for 2 h at 4 °C with agitation. Cells were 
then washed with flow cytometry buffer two times and incubated with 50 µl of fluorescently 
labelled mMCAM10 antibody (100 µg/ml) targeted at the same protein, for 1 h at 4 °C with 
agitation. Binding of the second antibody was analysed as in 2.9.1. 
2.9.3. Flow cytometry for propidium iodide staining 
Cells were detached using Trypsin-EDTA and washed with PBS. Cells were again 
pelleted and fixed by the drop-wise addition of ice cold 100% ethanol while slowly vortexing. 
Cells were fixed in ethanol at -20 °C for 1 h. Cells were then centrifuged for 5 min to remove 
the ethanol and washed twice with PBS. Cells were then resuspended in 0.25% (v/v) Triton 
X-100 in PBS and incubated at 4 °C for 15 min with agitation. Cells were spun down and washed 
with PBS. Finally, 470 µl of PBS was added to the cell pellet and the cells transferred to a flow 
cytometry tube. 5 µl of 0.1 mg/ml of RNAse A and 25 µl of 50 µg/ml of propidium iodide was 










2.10 Immunostaining of cells and tissues 
2.10.1. Immunofluorescence staining of paraformaldehyde fixed cells on coverslips 
Cells were seeded in complete medium on round (13 mm) coverslips coated with 0.1% 
(w/v) gelatin, in 6-well plates. After attaching for 24-48 h, cells were washed 3 times with PBS 
(washing step) and fixed with 4% (w/v) paraformaldehyde (PFA) in PBS for 10 min at room 
temperature. This was followed by a washing step, and then with incubation with 50 mM 
NH4Cl in PBS for 10 min at room temperature and another washing step. Cells were then 
blocked with blocking buffer [PBS, 3% (w/v) BSA, 10% (v/v) FCS, 0.1% (v/v) Tween 20] for 1 h 
at room temperature. Cells were then incubated for 1 h at room temperature with 50 µl of 
primary antibody or the same species nonspecific IgG diluted in blocking buffer (final 
concentration 10 µg/ml). Antibody solution was washed, and the coverslips were incubated 
with fluorescently labelled appropriate secondary antibody (diluted 1:200 in blocking buffer) 
in the dark for 1 h at room temperature. Coverslips were washed 3 times with PBS and then 
with dH2O and mounted onto DAPI Prolong gold mounting medium (Invitrogen) on glass 
slides. Images were taken with a Leica DM6000 and analysed using ImageJ software. 
2.10.2. Embedding of cells into agarose blocks 
Cells were collected from plates using non-enzymatic cell dissociation solution and 
spun down at 196 x g for 5 min. The supernatant was removed, and the cells were 
resuspended in 300 µl of preheated 1% (w/v) low melting point agarose in PBS at 50 °C. The 









2.10.3. Tissue and cell preparation for immunostaining  
Mouse tissue and agarose embedded cells for immunohistochemistry were fixed in 
formalin for 24 h and further processed, embedded in paraffin and sectioned by the 
Birmingham tissue bank. The slides were stored at room temperature until used.  
The tissue and agarose embedded cells used for frozen tissue immunofluorescence 
were immersed in OCT freezing medium and snap frozen. Tissue was then processed and 
sectioned by the Birmingham tissue bank, and slides stored at -80 °C until used. 
2.10.4. Immunofluorescence staining of frozen sections  
Frozen agarose embedded cells and frozen mouse tissue were used for 
immunofluorescence staining. Sections were thawed at room temperature for 10 min, 
followed by fixing in acetone at -20 °C for another 10 min. Slides were then washed 3 times 
for 5 min with PBS. Shandon coverplates (Thermo Fisher) were placed on top of the tissue 
slides and placed into a Sequenza slide rack (Thermo Fisher). Tissue was blocked with 100 µl 
of 2.5% (v/v) horse serum (Vector laboratories, Orton, UK) at room temperature for 30 min. 
Species nonspecific IgG (10 µg/ml in PBS), or undiluted supernatants were added in 100 µl to 
the slides and incubated at room temperature for 1 h. Slides were then washed 3 times with 
2 ml of PBS and the secondary antibody conjugated to a fluorophore (diluted 1:200 in PBS) 
was added. This was incubated for 1 h at room temperature in the dark and the slides washed 
as previously. Slides were additionally washed with 1 ml of dH2O, mounted with DAPI prolong 
gold mounting media (Invitrogen) and then coversliped. Sections were imaged using a Leica 
DM6000. In the case of the antibody localisation experiment, the incubation with primary 








2.10.5. Immunohistochemistry staining of formalin-fixed paraffin-embedded cells and 
tissues 
Formalin-fixed agarose embedded cells and formalin-fixed mouse tissues were used 
for immunohistochemical staining. Cells and tissues were fixed in formalin for 24 h, and then 
processed, embedded in paraffin and sectioned by the Birmingham tissue bank. Slides were 
heated at 60 °C for 30 min, and deparaffinised by immersion in xylene (Acros Organics) 3 times 
for 2 min. Slides were then hydrated by incubation in 100%, 95% and 75% (v/v) ethanol for 2 
min each, followed by incubation 2 times in dH2O for 2 min. After this, slides were incubated 
in 3% (v/v) hydrogen peroxide in methanol for 5 min. Slides were then washed 3 times with 
PBS-T and subjected to antigen unmasking with either Sodium Citrate based (pH 6), or Tris 
based (pH 9) unmasking solution (Vector laboratories), by boiling in the microwave at 900 W 
for 15 min. The slides were cooled under running tap water for 30 min. Next, the slides were 
blocked with 2.5% (v/v) horse serum (Vector laboratories) for 1 h at room temperature and 
probed with monoclonal antibodies mMCAM10, mMCAM66 or control rat IgG at a 
concentration of 15 μg/ml for 1h at room temperature. The slides were then washed with PBS 
and incubated with HRP conjugated anti-rat secondary antibody diluted (1:100) in 2.5% horse 
serum for 45 min at room temperature. The reaction was developed using peroxidase 
substrate kit (ImmPACT™ NovaRED™, Vector laboratories) for approximately 5 min and 
immediately immersed in dH2O for 5 min. Slides were then immersed in haematoxylin solution 
(Pfm Medical) for 2 min and washed with dH2O for 1 min. Slides were incubated under running 
tap water for 5 min, and with dH2O for 5 min. Finally, slides were dehydrated in 70%, 95% and 
100% ethanol for 2 min each, and immersed in xylene 3 times for 2 min. Slides were mounted 









bEND cells were lysed in NP-40 lysis buffer by the protocol described in 2.3.4. The cell 
lysate supernatant (1 ml) was pre-cleared by first incubating with 50 μl of protein G beads 
with 1 μg/ml of rat IgG control for 1 h at 4 °C on a wheel. Beads were centrifuged, and the 
supernatant collected and then incubated with 2 μg/ml of individual rat monoclonal 
antibodies or rat IgG control overnight at 4 °C with agitation. The following day 20 μl of protein 
G beads were added to the lysates with antibodies/IgG and incubated for 1 h at 4 °C. The 
beads were centrifuged, washed 4 times with beads wash buffer and boiled at 95 °C in 








2.12 Mouse tumour implantation and antibody injection 
RENCA cells were cultured for 1 week before the experiment. The cells were collected 
from the plates by pipetting and centrifuged at 196 x g for 5 min. Cells were diluted in basal 
DMEM at 1x106 cells per 100 μl and kept on ice. 8-week-old male Balb/c mice were injected 
with 1x106 RENCA cells subcutaneously on the side of the body. Tumours were measured 
twice a week until they reached 1 cm3. The purified monoclonal antibodies in PBS (20 μg in 
total) were injected into the tail vain. Mice were monitored for 1 hour and then culled. The 








2.13 Sequencing the variable regions of monoclonal antibodies 
2.13.1. mRNA extraction and reverse transcription 
Rat hybridoma cells were collected from plates and spun down in an amount of up to 
5x106 cells. RNeasy RNA Purification kit (Qiagen) was used to isolate the mRNA as 
recommended by the manufacturer. Cells were lysed in 350 µl of RTL buffer, containing β-
mercaptoethanol. The lysate was disrupted by centrifugation through Qiagen qiashredder 
column (Qiagen) at a maximum speed (16602 x g) for 2 min. 350 µl of 70% (v/v) ethanol was 
added to the lysate and mixed by pipetting. This was transferred to the RNeasy spin column 
and centrifuged for 15 sec at 7379 x g, and the flow-through discarded. 700 µl of RPE buffer 
was added to the column, centrifuged for 15 sec at 7379 x g, and the flow-through discarded. 
500 µl RPE buffer was added to the column, centrifuged for 2 min at 7379 x g, and the flow-
through discarded. The column was placed in a clean collection tube, 30 µl of nuclease free 
water was added directly to the membrane and centrifuged for 1 min at 7379 x g. The 
concentration of mRNA was checked by a NanoDropä. The RNA was stored at -80 °C. Reverse 
transcription to generate cDNA was carried out using QuantiTect® Reverse Transcription kit 
(Qiagen), following manufacturer’s instructions. First, the genomic DNA was removed using 
gDNA Wipeout buffer (Table 2.12) by incubating the reaction at 42 °C for 2 min. This RNA was 
then used with reverse-transcription master mix (Table 2.13) and incubated at 42 °C for 1 h, 
and then at 95 °C for 3 min to inactivate the reverse transcriptase. The RT primer mix provided 
in the kit was a mix of oligo-dT and random primers in order to generate high yields of cDNA 









Table 2.12 Genomic DNA removal reaction 
Component  Volume/reaction 
gDNA Wipeout Buffer, 7x 2 µl 
Template RNA 1 µg of RNA  
RNase-free water Up to 14 µl 
Total volume 14 µl 
 
Table 2.13 Reverse transcription reaction 
Component  Volume/reaction 
Quantiscript Reverse Transcriptase 1 µl 
Quantiscript RT Buffer, 5x 4 µl 
RT Primer Mix  1 µl 
Template RNA 14 µl of previous reaction 
Total volume 20 µl 
 
2.13.2. Addition of the Poly-C tail to the cDNA 
Addition of poly C chain to the cDNA 3’ end was carried out with a terminal transferase 
kit (NEB). The DNA was heated to 95 °C for 1 minute and immediately chilled on ice. The 
terminal transferase reaction was assembled (Table 2.14) and incubated at 37 °C for 30 min, 
and then at 75 °C for 30 min. 500 µl of nuclease free H2O was added, and the solution was 
concentrated down in an Amicon ultra-0.5 centrifuge filter column (Millipore) to 
approximately 5 µl. 
 
Table 2.14 Terminal transferase reactions 
Component  Volume/reaction 
Molecular biology H2O 6 µl 
Terminal transferase buffer (10X) 2 µl 
dCTP 20 mM 1 µl 
Terminal transferase 1 µl 
Template cDNA 10 µl 










2.13.3. Rapid amplification of cDNA ends (RACE) PCR  
Dr Steve Lee, University of Birmingham, kindly provided primers for the RACE PCR 
reactions (Table 2.15). 
Table 2.15 Primer list for RACE PCR; W: A or T; I: Inosine 
Primer Name (S.L.*) Primer description Sequence 
pGI-TdT  Poly G-anchor primer ACG GTG CAA ACC TTC CTC 
CAA ATC GGG IIG GGI IGG GII  
 
rtIGHG1/2A Rat IgG1 heavy chain constant 
region specific outer primer 
TCC CAG GGT CAC CAT GGA 
GTT AC 
 
rtIGKC Rat kappa light chain constant 
region specific outer primer 
GAT ACA CGA CTG WGG CAC 
CTC CAG T 
 
pGI-TdT anchor Anchor primer  ACG GTG CAA ACC TTC CTC 
CAA ATC GGG 
 
rtIGHG1/2A nest Rat IgG1 heavy chain constant 
region specific inner primer 
GTC ACC ATG GAG TTA CTT 
TTG AGA GCA GT 
 
rtIGKC nest Rat kappa light chain constant 
region specific inner primer 
GGA AGA TRG ATA CAG TTG 
GTG CAG CAT C 
 
*provided by Dr Steve Lee, University of Birmingham 
First PCR 
The DNA from previous terminal transferase reaction was used as a template for the 
first PCR in the RACE PCR protocol (C-tailed cDNA). The forward primer used was specific for 
the poly-C tail added to the cDNA and contained an anchor sequence at the end (pGI-TdT) that 
was used as a recognition sequence for the second PCR (pGI-TdT). The reverse primer used 
was the specific outer primer for the rat IgG1 or rat kappa constant region (rtIGHG1/2A and 
rtIGKC, respectively). The Platinum PCR supermix (Thermo Fisher) was used to amplify the 











DNA from first PCR was used as a template for the second RACE PCR reaction (PCR1 
product). The Platinum PCR supermix (Thermo Fisher) was used to amplify the DNA following 
manufacturers recommendations (Table 2.16 and Table 2.17) using forward anchor primer 
(pGI-TdT anchor) and reverse specific inner primer for the constant region of the rat IgG1 or 
rat kappa (rtIGHG1/2A nest and rtIGKC nest, respectively). The polymerase enzyme from the 
Platinum PCR supermix adds 3´-adenine overhangs to the PCR product. 
Table 2.16 PCR reaction mix reagents  
Component  Volume/reaction 
Platinum mastermix 47 µl 
C-tailed cDNA/PCR1 product 1 µl 
Primer Forward 25 µM 1 µl 
Primer Reverse 25 µM 1 µl 
Total volume 50 µl 
 
Table 2.17 PCR reaction conditions 
temp  time cycles 
94 °C 2 min  
94 °C 30 sec  
56 °C 30 sec 26 x 
72 °C 90 sec  
72 °C 10 min  
4°C  ∞  
2.13.4. Cloning of variable regions into TOPO vector 
TOPO® TA Cloning® was used for the direct insertion of the amplified variable regions 
from the RACE PCR protocol with single 3´-adenine (A) overhangs into a TOPO vector 
[linearised with single 3´-thymidine (T) overhangs]. Topoisomerase I is covalently bound to the 
vector so the ligation is performed in 5 min at room temperature. The reaction was carried 
out according to the manufacturer’s recommendations (Table 2.18) and used to directly 









Table 2.18 TOPO cloning reaction 
Reagent  Volume 
PCR product 1 µl 
Salt solution 1 µl 
Water  3 µl 
TOPO® vector 1 µl 










2.14 Angiogenesis assays 
2.14.1. Cell proliferation analysis 
CellTiter 96® Non-Radioactive Cell Proliferation Assay (Promega, Southampton, UK) 
was used for cell proliferation analysis. HUVECs were seeded in 0.1% (w/v) gelatin in PBS 
coated 96-well plates at a density of 5,000 cells/well in a volume of 100 µl and cultured at 37 
°C in complete M199 medium. hMCAMecd-Fc protein or control Fc protein were added at a 
concentration of 1.54 µM. After 24, 48 or 72 h of cell growth, the medium was removed, and 
cells washed once with PBS. 100 µl of Opti-MEM with 15 µl of Dye Solution was added to the 
wells and the cells incubated for 4 h at 37 °C, after which the reaction was stopped with 100 
µl of Solubilisation solution/Stop mix. The plates with cells were left overnight at 4 °C and the 
absorbance at 570 nm was recorded using a Versa max microplate reader.  
2.14.2. Endothelial cell migration assay 
HUVECs were seeded on gelatin coated 96 well plates (IncuCyte 96-Well ImageLock, 
Essen Bioscience), 5,000 cells/well and left to adhere and form a monolayer over 1-2 days. A 
wound in the cell monolayer in the middle of the wells was made using an IncuCyte 
WoundMaker (Essen Bioscience). The detached cells were washed away with 100 µl PBS and 
fresh complete M199 medium containing recombinant proteins (hMCAMecd-Fc protein or 
control Fc protein at 1.54 µM concentration) was added. The assay was carried out at 37 °C 
and 5% CO2. Cell migration towards the closure of the wound was imaged with an IncuCyte 
ZOOM Live-Cell analysis system (Essen Bioscience) at 0, 6, 12, 18 and 24 h. Photos of cells were 
processed using IncuCyte ZOOM software and the percentage of wound closure was analysed 








2.14.3. Chemotactic transmigration of endothelial cells through a semipermeable 
membrane 
FluoroBlok HTS 24 Well Plate Cell Culture Inserts (Falcon) with 8.0 µm High Density PET 
Membrane (FloroBlock insert) were used in the HUVEC transmigration assay. 24 well tissue 
culture plates were used to hold the inserts and the bottom compartment was in all conditions 
filled with 700 µl of complete M199 medium containing FCS and bovine brain extract. 
FluoroBlock inserts were coated with 0.1% (w/v) gelatin in PBS for 30 min at 37 °C. HUVECs 
were incubated (‘starved’) in serum free M199 (without FCS and bovine brain extract) 1 h prior 
to seeding. Cells were then detached with Trypsin-EDTA and added to the gelatin coated 
inserts at 3x104 cells/well in 300 µl serum free M199 containing either hMCAMecd-Fc protein 
or control Fc protein at a concentration of 1.54 µM. The inserts with cells were placed in wells 
containing complete medium. Cells were left to migrate through the membrane for 5 h at 37 
°C. The inserts with cells were then washed twice with PBS and fixed in 4% (w/v) PFA. The 
membrane was cut out and mounted on in situ mounting medium with DAPI (Duolink) on the 
glass slide. Transmigrated cells were imaged using an Olympus 1X2-UCB fluorescent 
microscope under 10X magnification and nuclei were counted in 9 fields of view per insert 
using ImageJ software. 
2.14.4. Endothelial cell network formation in 2D matrigel assay 
Matrigel was taken from -80 °C freezer the day before the assay and left to thaw 
overnight on ice. On the following day, the wells of a 12 well tissue culture plates were rinsed 
with sterile PBS, which was immediately aspirated leaving a thin layer of PBS in the well, in 
order to easily and equally spread the matrigel. 70 µl of matrigel was added to the wells and 








140,000 cells per well in 1 ml of complete M199 medium (containing 1.54 µM hMCAMecd-Fc 
or Fc) on the matrigel coated wells. Cells were incubated at 37 °C, 5% CO2 and imaged in the 
IncuCyte ZOOM Live-Cell analysis system. The assay was monitored every 6 h over a period of 
24 h. Statistical analysis were carried out on a number of different measures such as tube 
number, length and branching and number of meshes. 
2.14.5. Endothelial cell network formation in a 2D fibroblast co-culture assay 
Human dermal fibroblasts were cultured on a 24 well tissue culture plate to 
confluence. HUVECs were seeded on top of the HDF cells at 1.5x104 cell/well in complete 
M199 medium containing recombinant proteins (hMCAMecd-Fc and Fc). The experiment was 
carried out for 6 days with a change of medium every two days. Cells were then fixed with 4% 
(w/v) PFA for 15 min at room temperature. PFA was washed twice with PBS and the cells 
incubated with 0.1% (v/v) Triton X-100 in PBS for 4 min at 4 °C. This was washed 3 times with 
PBS and the cells blocked with 1% (w/v) BSA in PBS for 1 h at room temperature. The cells 
were stained with anti-CD31 antibody (1:200) in blocking buffer for 1h at room temperature. 
The primary antibody was washed 3 times with PBS and the cells probed with secondary 
antibody conjugated to alkaline phosphatase (1:500) for 1 h at 37 °C. Cells were washed 2 
times with PBS and once with dH2O before developing the reaction with the chromogenic 
substrate BCIP/NBT for 25 min. The reaction was washed with dH2O and the cells dried before 
imaging with a Leica 10447157 microscope. The endothelial cell network formation was 








2.14.6. Endothelial cell network formation in 3D fibroblast co-culture assay 
HUVECs were lentiviraly transduced with GFP expressing plasmid two days prior to the 
experiment (as described in 2.4.4). Fibrinogen was dissolved in DPBS at a 2.5 mg/ml final 
concentration and filter sterilized. 47.5 µl of sterile aprotinin was added per 1 ml of fibrinogen. 
HUVECs (8x105 cells) and HDF cells (4x105 cells) were mixed together in a 1.5 ml eppendorf 
tube and spun down. The supernatant was removed, and the cells gently resuspended in 1 ml 
fibrinogen/aprotinin solution and kept on ice. 1 µl of 5U/ml thrombin was added to the middle 
of each well of the µ-Plate Angiogenesis 96-well plate (IBIDI), followed by the addition of 9 µl 
of the cell mix. Plates with cells were incubated for 40 min in the cell culture incubator at 37 
°C, after which the cells were overlaid with 70 µl of complete EBM-2 medium containing the 
different conditions of proteins. The assay was monitored throughout 10 days using the 
Olympus 1X2-UCB fluorescent microscope and the medium was replaced every other day. 
After a 10-day period cells were fixed in 4% (w/v) PFA for storage. The network formation was 
analysed using ImageJ software and angiogenesis analyser plug-in. 
2.14.7. Statistical analysis 
Statistical analyses were carried out using Graphpad Prism software version 7.0c (La 
Jolla, CA, USA). Paired student’s t test was used for single data comparisons in angiogenesis 
assays, while two-way ANOVA was used for three or more comparisons. Statistical significance 
was considered for p < 0.05 and indicated in figures by an asterisk (*). 










Renal cell carcinoma (RCC) is often correlated with the loss of function of the von 
Hippel Lindau factor (VHL). This loss of function promotes strong angiogenic signalling due to 
elevation of HIF-1 levels and increased VEGF expression, leading to highly vascular tumours 
133. Targeting blood vessels in RCC is well established, however many patients develop severe 
side effects, resistance to therapy and recurrence of the disease 49,134. Therefore, a new 
approach is much needed. MCAM is highly expressed on the tumour vasculature of RCC, 
correlating with the stage of cancer and poor patient prognosis 56. Thus, developing a 
monoclonal antibody towards MCAM could enable the development of new therapies for 
renal cell carcinoma.  
To further investigate MCAM as a target in RCC, we aimed to generate new monoclonal 
antibodies to MCAM. Our group had previously generated antibodies by immunizing mice 
with recombinant mouse CLEC14A protein 135. This yielded five monoclonal antibodies with 
cross reactivity to mouse and human CLEC14A. The same approach was successfully used in 
mouse ROBO4 vaccination of mice 136 and extra domain B of fibronectin (ED-B) vaccination of 
tumour bearing mice 137.  
This chapter will describe the production and purification of recombinant mouse and 
human MCAM (m/hMCAM) proteins, and their use to immunise rodents. The chapter will 
describe rodent immunisation, assessments of immune responses, fusions of splenocytes with 
myeloma cells and screening of positive hybridomas. Finally, this chapter will report the 









3.2 Production and purification of recombinant MCAM proteins  
3.2.1. Production of mMCAMecd-Fc recombinant protein 
Attempts to immunise mice with self-protein encounters the barrier of immunological 
tolerance. As a result, generating a high antibody titre sufficient to enable successful fusion is 
often not achieved. Our group has successfully broken tolerance in mice to several self-
proteins by using a human IgG1 Fc fusion tag and a strong adjuvant. Therefore, the Fc fusion 
tag was added to the C-terminal end of the extracellular domain of mMCAM (mMCAMecd-
Fc), depicted in Figure 3.1 A and the protein used in mouse and rat immunisations. The human 
Fc tag was incorporated by cloning of the extracellular domain of mMCAM protein into the 
pcDNA-Fc (pIg) vector 138. This vector contains the human Fc sequence. The cloning was 
performed by Dr Victoria Heath, University of Birmingham.  
HEK293T cells were PEI transfected with mMCAMecd-Fc or with the empty pIg vector. 
Cells were cultured to confluence in complete DMEM, before the medium was changed to 
serum free Opti-MEM. The expression of mMCAMecd-Fc protein was confirmed by Western 
blotting, using anti-human Fc (A0170, Sigma), and anti-mMCAM antibodies (AF6106, R&D). 
Thus, the mMCAMecd-Fc protein was successfully expressed by cells and secreted into the 
cell culture medium (Figure 3.1 B).  
Small scale protein pull-down from the medium was performed by incubating 1 ml of 
conditioned Opti-MEM (collected 48h after addition to transfected cells) with a small amount 
of Protein A beads overnight. The beads were washed, boiled in reducing protein loading 
buffer and the proteins run on an SDS-polyacrylamide gel that was then stained with 








to the beads and was not degraded (Figure 3.1 C). Comparison to BSA standards showed there 
was around 10 µg of protein per 1 ml of medium.  
To obtain at least 10 mg of protein, large-scale production was carried out. HEK293T 
cells were expanded to ten 15 cm cell culture dishes; transfected with the mMCAMecd-Fc 
plasmid and after reaching confluence, the medium was replaced by serum free Opti-MEM. 
Opti-MEM was collected every third day over two weeks. Medium (around 1 litre) containing 
the protein was filtered, run through a Protein A column and the protein eluted at pH 3. The 
elution fractions with the highest concentration of protein were loaded on an SDS- 
polyacrylamide gel and stained with Coomassie blue (Figure 3.1 D). The protein yield was >10 
mg/litre of medium. The elution fractions were pooled and dialysed to exchange the elution 











Figure 3.1 Production and purification of mMCAMecd-Fc recombinant protein. A) Schematic image 
of the extracellular domain of mMCAM fused to the human Fc tag; B) Western blot of 10 μl of 
supernatants from the HEK293T cells taken two days after transfection with empty pIg vector (ctrl) and 
mMCAMecd-Fc (mM-Fc) blotted with anti-human Fc antibody (α-Fc) and anti-mMCAM antibody (α-
mMCAM); C) Coomassie blue staining of small scale protein pull down with Protein A beads from the 
mMCAMecd-Fc and pIg transfected HEK293T cell media (1 ml), 20 μl of beads were loaded on the gel, 
BSA standard in µg; D) Coomassie blue staining of large scale purification of mMCAMecd-Fc on a 
Protein A column, 1 μl of elution fractions with the highest amount of protein was loaded on the gel, 









3.2.2. Production of mMCAMecd-His and hMCAMecd-His recombinant proteins 
To probe the antibody reactivity to the mMCAM protein and screen rodent plasma 
antibody titre, a recombinant mMCAMecd was cloned containing a 6xHis tag (mMCAMecd-
His), (Figure 3.2 A). This His-tagged MCAM allowed identifying antibodies that recognise the 
extracellular domain of MCAM by ELISA, or Western blot. A human version of the MCAM 
extracellular domain containing a 6xHis tag (hMCAMecd-His) was also produced and used to 
screen for antibodies that may have dual reactivity, towards mouse and human protein. 
m/hMCAMecd-Fc plasmids were used in the cloning. The Fc sequence was excised from both 
plasmids using NotI and XbaI restriction enzymes and the 6xHis sequence was inserted (using 
T4 ligase) at the C-terminal end of h/mMCAMecd in pIg vector (detailed protocol can be found 
in material and methods). 
HEK293T cells were PEI transfected with mMCAMecd-His/hMCAMecd-His or with the 
empty pIg vector, and grown in complete DMEM to confluence, when the medium was 
changed to serum free Opti-MEM. The expression of proteins was confirmed by Western 
blotting using anti-His antibody (MAB050, R&D), and anti-mMCAM (AF6106, R&D) or anti-
hMCAM (HPA008848, Sigma). Both proteins were expressed by cells and secreted into the 
media (Figure 3.2 B and Figure 3.3 A).  
Small scale protein pull-down from the medium was carried out by incubating 1 ml of 
conditioned Opti-MEM cell medium (collected 48h after addition to cells), with a small amount 
of Ni-NTA beads overnight. The beads were washed, boiled in reducing protein loading buffer, 
run on an SDS-polyacrylamide gel, and proteins stained with Coomassie blue. The proteins 








HEK293T cells were expanded to ten 15 cm cell culture dishes; transfected with the 
mMCAMecd-His/hMCAMecd-His and after reaching confluence, serum free Opti-MEM was 
used to replace DMEM. Opti-MEM was collected every three days over two weeks. The 
medium containing the protein was filtered, run through a Ni-NTA column and eluted with 
250 mM imidazole in 0.5 ml fractions. The elution fractions with the highest concentration of 
protein were loaded onto an SDS-polyacrylamide gel and stained with Coomassie blue (Figure 













Figure 3.2 Production and purification of mMCAMecd-His recombinant protein. A) Schematic image 
of the extracellular domain of mMCAM fused to the 6xHis tag; B) Western blot of 10 μl of supernatants 
from the HEK293T cells taken two days after transfection with empty pIg vector (ctrl) and mMCAMecd-
His (mM-His) blotted with anti-His antibody (α-His) and anti-mMCAM antibody (α-mMCAM); C) 
Coomassie blue staining of small scale pull down with Ni-NTA beads from the mMCAMecd-His and pIg 
transfected HEK293T media (1 ml), 20 μl of beads were loaded on the gel, BSA standard in µg; D) 
Coomassie blue staining of large scale purification of mMCAMecd-His on a Ni-NTA column, 1 μl of 











Figure 3.3 Production and purification of hMCAMecd-His recombinant protein. A) Western blot of 10 
μl of supernatants from the HEK293T cells taken two days after transfection with empty pIg vector 
(ctrl) and hMCAMecd-His (hM-His) blotted with anti-His antibody (α-His) and anti-hMCAM antibody 
(α-hMCAM); B) Coomassie blue staining of small scale protein pull down with Ni-NTA beads from the 
hMCAMecd-His and pIg transfected HEK293T media (1 ml), 20 μl of beads were loaded on the gel, BSA 









3.3 Papain cleavage of the Fc tag from mMCAMecd-Fc 
Following initial immunisation with mMCAMecd-Fc, the titre in mice showed a strong 
response to the human Fc tag but not to the mouse MCAM self-antigen. To increase the 
immune response to mMCAM protein and prevent a stronger response to the human Fc tag, 
the tag was removed by cleavage with the protease papain (Figure 3.4 A). The cleaved protein 
was then used to boost mouse and rat immunisation. 
Optimisation of papain cleavage  
Papain cleaves the Fc tag but at the same time degrades the protein and so it was 
essential to optimise the time point at which the amount of cleaved mMCAMecd peaked. The 
mMCAMecd-Fc protein was mixed with the papain cleavage buffer to a final concentration of 
0.3 µg/µl to enable protein to be visualized on an SDS-polyacrylamide gel (Coomassie blue 
readily stains 3 µg of protein on this size of gel). Thus, 10 µl of this reaction was sampled as a 
starting point before addition of papain. The reaction mixture was then sampled over one 
hour and analysed by protein separation by SDS-polyacrylamide gel electrophoresis and 
stained with Coomassie blue. The mMCAMecd-Fc band at the start was much greater than the 
bands after addition of papain. The reason for this could be that the reaction was not fully 
quenched by the addition of reducing protein loading buffer and storing the samples on ice 
before boiling at 95 °C. Thus, when on ice, papain was probably still catalytically active. Over 
the course of 60 min, almost all the protein was cleaved, however, the greatest amount of 
cleaved mMCAMecd as shown on the gel was reached at 30 min. After that the cleaved protein 











Figure 3.4 Optimisation of papain cleavage of the Fc tag from mMCAMecd-Fc. A) Schematic image of 
papain cleavage of mMCAMecd-Fc at the connection of MCAM extracellular domain and the Fc tag, 
Protein A beads capture cleaved Fc tag leaving the purified mMCAMecd; B) mMCAMecd-Fc protein 
was cleaved using protease papain at 37 °C in a 100 µl reaction with 10 µl sample collection at time-
points over 1 hour, each sample was mixed with reducing SDS loading buffer and boiled at 95 °C before 
loading on the gel and visualised with Coomassie blue staining. Arrow showing the time-point at which 










Large scale papain cleavage and purification of the cleaved mMCAM 
A large scale papain cleavage of mMCAMecd-Fc was carried out in 1 ml of reaction mix 
with 300 µg of protein. After 30 min of cleavage, the reaction was quenched. Protein A beads 
were used to sequester the Fc tag. The reaction mixture was incubated with Protein A beads 
for 2 h at 4 °C, the beads were centrifuged, and the supernatant collected. The supernatant 
was incubated twice more with fresh Protein A beads. The final product was loaded on an 
SDS-polyacrylamide gel and examined by Western blot analysis with anti-human-Fc (A0170, 
Sigma) and anti-mMCAM (AF6106, R&D) to ensure that there was no Fc tag left (Figure 3.5 A). 
Coomassie blue staining of the gel confirmed the purity of the cleaved mMCAMecd (Figure 
3.5 B). Purified cleaved mMCAMecd was dialysed against PBS, sterile filtered and 










Figure 3.5 Large scale papain cleavage of mMCAMecd-Fc and Fc depletion. Large scale papain 
cleavage was carried out in 30 min reaction with 1.6 µg/ml papain; the Fc tag was removed by 
incubation with Protein A beads: A) Western blot with anti-mMCAM (α-mMCAM) and anti-human Fc 
(α-Fc) and B) Coomassie blue staining of mMCAMecd-Fc protein before papain cleavage (mMCAMecd-









3.4 Generation of monoclonal antibodies that recognise mMCAMecd in 
mice 
The previous successful attempts to generate an immune response to self-protein in 
mice used human Fc tag as a tool to break tolerance. To generate monoclonal antibodies 
towards mouse MCAM extracellular domain, purified mMCAMecd-Fc was used to immunise 
mice. Eurogentec S.A. biotech was employed to perform the immunisation and the purified 
protein was supplied to the company. The immunisation was as previously described for 
another self-antigen fused to the human Fc tag (mROBO4-Fc) 136 (section 2.8.1.1). In brief, 
mice were immunised every two-weeks using 50 µg of mMCAMecd-Fc in Freund’s complete 
adjuvant (FCA) for the first immunisation, and subsequently with Freund’s incomplete 
adjuvant (FIA) (Table 3.1).  
Pre-immunisation bleeds were collected as a negative control. Bleeds collected after 
the fourth immunisation were compared to the pre-immune bleeds by ELISA assay on 
mMCAMecd-Fc and mMCAMecd-His. 500 ng of protein was used to coat each well of an ELISA 
plate. The ELISA plates were probed overnight with the 1/500 bleed dilution in PBS. As 
expected the response (antibody titre) to mMCAMecd-Fc was strong, while a response to 
mMCAMecd-His was only detected in one mouse (mouse 33354) (Figure 3.6). Serial dilutions 
of bleeds were tested, however the response in mouse 33354 was seen only in the 1/500 










Table 3.1 Mouse immunisation protocol - Eurogentec S.A. 
Day Date Protocol: Standard Programme 
0 20/10/15 Preimmune bleed 
Injection with 50 µg mMCAMecd-Fc/Freund's complete adjuvant 
14 03/11/15 Injection with 50 µg mMCAMecd-Fc/Freund's incomplete adjuvant 
28 17/11/15 Injection with 50 µg mMCAMecd-Fc/Freund's incomplete adjuvant 
42 01/12/15 Injection with 50 µg mMCAMecd-Fc/Freund's incomplete adjuvant 






Figure 3.6 Screening mouse bleeds by ELISA. 500 ng per well of mMCAMecd-His and mMCAMecd-Fc 
was used to coat the ELISA plate; 1:500 dilutions of mouse bleeds were used to probe the ELISA and 
the absorbance was recorded at 490 nm. Unimmunised mouse bleed was used as a negative control, 




























































Splenocytes from the single positive mouse (M33354) were isolated and fused with 
mouse myeloma cells to generate antibody-producing hybridomas. Single sample of undiluted 
supernatants from pools of hybridoma cells were screened for reactivity towards the original 
immunogen mMCAMecd-Fc and the mMCAMecd-His protein to assess specificity of 
supernatants. The reactivity of supernatants was high to mMCAMecd-Fc but negative to 
mMCAMecd-His indicating that none of the antibodies recognised the mMCAMecd protein 
(Figure 3.7). Due to the small volume of the supernatants one repeat per hybridoma was 
tested by ELISA. 
Two further fusions were carried out with different immunisation protocols with 
mouse MCAM recombinant proteins. One attempt used a combination of immunisations with 
mMCAMecd-Fc and subsequent boosts with the cleaved mMCAMecd. Another attempt used 
only mMCAMecd cleaved throughout the immunisation protocol (protocols described in 












Figure 3.7 Screening hybridoma supernatants by ELISA. 500 ng per well of mMCAMecd-His and 
mMCAMecd-Fc was used to coat the ELISA plate; undiluted mouse hybridoma supernatants were used 
to probe the ELISA overnight and the absorbance was recorded at 490 nm. Secondary antibody only 
was used as a negative control, and 1 µg/ml of anti-His (MAB050, R&D) and anti-Fc (A0170, Sigma) 








































































3.5 Generation of monoclonal antibodies that recognise mMCAMecd in rats 
Repeated failure to break tolerance in mice to mouse MCAM prompted us to immunise 
rats with mouse MCAM. To confirm that there are amino acid sequence differences between 
the mouse and rat protein, the sequences of extracellular domains were compared using 
online Blastp program (protein-protein BLAST, NCBI), which showed 90% identity between 
these sequences. Praline (http://www.ibi.vu.nl/programs/pralinewww/) 139 online tool was 
used to map the conserved and non-conserved amino acid residue types to investigate if the 
differences between amino acid sequences are sufficient to promote an immune response in 
rat (Figure 3.8). There are several epitopes with poorly conserved amino acids, which led us 










Figure 3.8 Comparison of amino acid sequence of mouse and rat MCAM extracellular domain using 









Biogenes GmbH was sub-contracted to immunise rats with mMCAM recombinant 
proteins. A standard immunisation protocol was used, where rats were immunised at one-
week intervals according to the schedule in Table 3.2. In the first and the second 
immunisation, rats were immunised with 50 µg of mMCAMecd-Fc, while the rest of the boosts 
were carried out with 50 µg of the cleaved mMCAMecd (Table 3.2).  
 
Table 3.2 Rat immunisation protocol - Biogenes GmbH 
Day Date Protocol 
0 04/10/16 Preimmune bleed 
Injection with 50 µg mMCAMecd-Fc/ Freund's complete adjuvant 
7 11/10/16 Injection with 50 µg mMCAMecd-Fc/ Freund's incomplete adjuvant 
14 18/10/16 Injection with 50 µg mMCAMecd/ Freund's incomplete adjuvant 
21 25/10/16 Test bleed 
34 07/11/16 Final boost (rat 1, 3) 50 µg mMCAMecd/ Freund's incomplete adjuvant 
38 11/11/16 Fusions (rat 1, 3) 
131 13/02/17 Final boost (rat 2) 50 µg mMCAMecd/ Freund's incomplete adjuvant 
135 17/02/17 Fusions (rat 2) 
 
3.5.1. Screening of the immune response in rat serum by ELISA 
Pre-bleeds were taken from the rats as a negative control. Bleeds were taken one week 
after the 3rd immunisation and examined for serum antibodies to mMCAMecd-His and 
hMCAMecd-His. ELISA plates were coated with 500 ng of protein and probed overnight with 
serial dilutions of rat serum in PBS. All three rats showed a strong response to the mouse 
protein and a weak response to the human protein (Figure 3.9). Serum from unimmunised 

















Figure 3.9 Screening of the immune response in rat bleeds by ELISA. 500 ng of A) mMCAMecd-His 
and B) hMCAMecd-His was used to coat the ELISA plate. Serial dilutions of rat bleeds were used to 
probe the ELISA. Unimmunised serum (normal serum) was used as a negative control. The absorbance 









3.5.2. Screening of mMCAM positive hybridoma clones by ELISA 
Two rats (rat 1 and 3) were boosted with the final immunisation and culled for fusion 
three days later. Splenocytes were isolated and fused to mouse myeloma Sp2/0-Ag14 cells. 
These myeloma cells do not secrete immunoglobulin, are resistant to 8-azaguanine at 20 
μg/ml, lack hypoxanthine-guanine phosphoribosyltransferase (HGPRT) activity and are HAT 
sensitive (final concentration: hypoxanthine at 100 μM, aminopterin at 400 nM and thymidine 
at 16 μM). The supernatants of hybridoma cells from 2 culled rats were tested on mMCAMecd-
His ELISA at Biogenes. However, this fusion failed to generate stable antibody producing 
hybridomas.  
A third rat was left for a period of >3 months before another immunisation was 
performed again with Fc cleaved mMCAMecd. The rat was culled for splenocyte fusion with 
mouse myeloma cells 3 days later. Individual hybridoma clones were cultured in separate 
wells and the supernatants examined by ELISA on mMCAMecd-His protein at Biogenes (data 
not shown). A single sample for each individual hybridoma was tested by ELISA (due to 
supernatants’ volume restrictions) and a signal higher than the negative control was 
considered as reactive to MCAM. The plates were coated with 500 ng of mMCAMecd-His and 
hMCAMecd-His and probed with undiluted hybridoma supernatants, the positive control 
(anti-m/hMCAM at 1 µg/ml) or the negative control (myeloma cell supernatant). The response 
to mMCAMecd-His was variable with most of the supernatants strongly positive, but there 














Figure 3.10 Screening supernatants of rat hybridoma cells on A) mMCAMecd-His and B) hMCAMecd-
His ELISA. 500 ng of protein was used to coat the ELISA plate; undiluted hybridoma supernatants were 
used to probe the ELISA. The OD was measured at 450 nm – 590 nm to remove the background signal. 
Positive control 1 µg/ml anti-mMCAM (AF6106), anti-hMCAM (HPA008848), and negative control 
myeloma cell supernatant. 
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3.5.3. Screening of strongly positive mMCAM hybridoma clones by Western blot 
Thirty strongly positive hybridoma clones were selected for Western blot analysis. 
MCAM protein has five di-sulphide bonds within the extracellular domain, which are broken 
under reducing conditions. Individual supernatants were examined by Western blot to see if 
the antibodies recognise the protein in its reduced or non-reduced state. This showed 
whether antibodies recognise a linear epitope on mMCAM protein or the folded protein, 
which is dependent on the disulphide bonds. Mouse MCAMecd-His protein was loaded onto 
an SDS-polyacrylamide gel in reducing and non-reducing protein loading buffer. The protein 
was transferred to the PVDF membrane and the membrane cut into small pieces. Each piece 
of membrane was probed with an individual supernatant. The antibodies in supernatants 
appear to have different reactivity towards MCAM protein (Figure 3.11). Several antibodies 
recognise only the non-reduced form (4, 9, 26, 29, 35, 37, 40, 48, 53, 54, 55, 58, 63, 66, 70). 
The immunisations and screenings by ELISA were performed using non-reduced form of 
MCAM so it is expected that the antibodies detect either the non-reduced, or both reduced 
and non-reduced form of MCAM on Western blot. However, some antibodies give a high 
background staining such as antibody 2 and 3, while some do not recognise or only slightly 
recognise MCAM by Western blot (4, 9, 17, 58, 63 and 70). Antibodies 10, 15, 17, 20, 22, 24, 
34, 41, 46,51, 72, 75 and 81 recognise both the reduced and non-reduced MCAM, indicating 
they recognise the linear epitope. However, some have a stronger and some weaker binding 












Figure 3.11 Western blot with individual hybridoma supernatants on non-reducing (left) and 
reducing (right) mMCAMecd-His protein. The proteins were loaded on an SDS-polyacrylamide gel and 
transferred to the PVDF membrane; the membrane was cut in small strips at the site of the protein 











3.6 Sub-cloning of selected hybridoma clones 
Based on the Western blot and ELISA analysis, ten hybridoma clones were selected for 
further sub-cloning, namely 3, 9, 17, 20, 46, 48, 53, 54, 72 and 75. BioGenes additionally 
selected primary cultures number 10, 26, 35, 41 and 66 for sub-cloning. Each of these colonies 
were diluted to form single cells seeded in the wells by limiting dilution. Only wells with single-
cell colonies were tested further for mMCAM recognition. Supernatants were tested on ELISA 
plates coated with mMCAMecd-His protein. The final bleed dilution was used as a positive 
control (antiserum) and myeloma cell supernatant as a negative control. After the first sub-
cloning, clone numbers 10-2, 46-16 and 66-11 continued to secrete antibodies with the 
expected reactivity profile (Table 3.3). All other primary cultures stopped generating 
antibodies during the first sub-cloning. 
All primary hybridomas were, however, frozen before the first sub-cloning and so in 
principle the variable regions can be recovered from their mRNA by retro-transcription and 
PCR with specific primers after cell recovery.  
 
Table 3.3 ELISA results after 1st sub-cloning. The ELISA plates coated with mMCAMecd-His were 
probed with the supernatants of positive clones 10-2, 46-16 and 66-11, final bleed dilution (Antisera) 
and myeloma cell supernatant (Negative control). The optical density was recorded at 405 nm. 




Antiserum (1:100) 3.834 










3.7 Generation of stable hybridoma cell lines producing monoclonal 
antibodies to mMCAM 
After the second sub-cloning, clones 10-2-1 and 66-11-5 continued to stably produce 
antibodies against mMCAMecd-His (Table 3.4). Clone 46-16 lost antibody production during 
the second cloning procedure. These cells were passaged several times to identify the best 
clones with regard to cell growth and ELISA signal. Finally, hybridoma cell lines with the stable 
production of monoclonal antibodies that recognised mMCAMecd were generated and used 
for antibody production and characterisation described in chapter 4 of this thesis. Both 
hybridomas were confirmed to be mycoplasma-free by Greiner Bio-One GmbH, 
Frickenhausen, Germany, and were cryopreserved. 
 
Table 3.4 ELISA results after 2nd sub-cloning. The ELISA reaction was carried out on plates coated with 
mMCAMecd-His protein; the supernatants of positive clones 10-2-1, and 66-11-5 were compared with 
final bleed dilution as a positive control (antisera) and myeloma cell supernatant (negative control). 
The optical density was recorded at 405 nm. 
Clone number ELISA reaction absorbance at 405 nm 
10-2-1 1.277 
66-11-5 0.766 
Antiserum (1:100) 1.293 













To explore the therapeutic potential of MCAM in a renal cancer mouse model, we 
aimed to generate monoclonal antibodies that recognise the extracellular domain of mouse 
MCAM protein. Targeting the extracellular domain of endothelial proteins has clear 
advantages over targeting tumour cells because they are accessible by agents circulating in 
the blood and since they are part of the stromal compartment they should not develop 
resistance to therapy. Monoclonal antibody generated in mice would have little risk of 
mounting a subsequent immune reaction and would thus be optimal for tumour targeting 
experiments in mice. Previous work showed that fusing a self-antigen to a foreign protein such 
as human Fc and using a strong adjuvant (such as Freund’s complete adjuvant) increased 
recognition of T-cell helper lymphocytes and generated a stronger B cell response 137,140. 
However, several attempts to raise an immune response to MCAM self-protein in mice failed 
to generate positive hybridoma cells. Tolerance to this self-antigen was much stronger than 
previously encountered by our group with other proteins 136,135. In agreement with this, other 
groups showed that antibodies against human MCAM developed in mice could recognise the 
human protein but not the mouse one, even though the similarity between the two is 75%, 
showing a strong tolerance to mouse antigen 58. One group described six novel anti-hMCAM 
antibodies generated in mice with none of them being able to recognise the mouse protein 
141. High levels of MCAM during embryonic development could explain the tolerance to this 
self-protein. MCAM is found highly expressed on embryonic tissue of spleen, thymus and bone 
marrow 67,142, tissues of maturation and deletion of self-recognising immune cells. However 








Protein sequence similarity between the mouse and rat MCAM extracellular domain is 
90%, indicating that a non-self response to certain parts of protein should be possible. Thus, 
rat immunisation resulted in around 50 positive primary hybridoma cells. All of these were 
frozen immediately after confirmation of positivity in order to be able to sequence the variable 
regions of the heavy and light immunoglobulin chains. Ten hybridomas were chosen for 
further sub-cloning, but in the process,  all lost recognition of mouse MCAM. However, two 
other clones, selected by Biogenes were sub-cloned and created stable hybridomas. Fusion 
with rat myeloma cells would possibly have generated a larger number of hybridoma clones, 
however fusion with mouse myeloma cells was an established protocol within Biogenes and 
was thus, performed in this study. 
The primary aim was to generate antibodies with reactivity towards mouse and human 
protein. This would enable investigation of antibodies function in mouse models and further 
validation of antibodies on human tissue. Rat serum antibodies showed a slight response to 
the human protein, however, none of the generated hybridoma antibodies could recognise 
the human protein. Potentially, boosting rats with hMCAMecd-Fc recombinant protein would 
increase the amount of dual reactivity antibodies, and this strategy could be used in future 
immunisation. Additionally, many new strategies involving synthetic antibody libraries, such 
as phage and yeast display libraries could be utilised to generate antibodies towards shared 
epitopes in human and mouse protein. 
Despite the fact that the antibodies were generated in rats, the antibody variable 
regions can be grafted onto a mouse main frame, enabling their use in mouse models of 
cancer. Thus, further molecular engineering is necessary in order to develop mouse anti-








Finally, the hybridoma clones were tested for antibody reactivity by Western blot in 
reduced and non-reduced conditions. MCAM protein contains 5 disulphide bonds and thus, 
antibodies that recognise epitopes dependent on these bonds would not be able to recognise 
the reduced form of MCAM by Western blot. Different patterns were observed with 
hybridoma supernatants indicating various binding properties of the generated antibodies. 
Sequencing variable regions would discover the differences between each individual clone. 
The primary hybridoma clone 10 recognised both reduced and non-reduced form of MCAM, 
although the band on Western blot for reduced protein was much fainter than on the non-
reduced sample. However, primary hybridoma clone 66 did not recognise the reduced form 
of MCAM but only non-reduced.  
These hybridoma cells were sub-cloned to generate stable cell lines producing reactive 
MCAM antibody and in the next chapter further characterisation of these antibodies will be 
performed and their specificity and biology investigated in greater depth.  
4 BIOCHEMICAL CHARACTERISATION OF RAT MONOCLONAL 









Monoclonal antibodies are a valuable and widely used tool in scientific research and 
medicine. For example, monoclonal antibodies targeting EGFR, HER2 and VEGF are routinely 
used in cancer treatment and have significantly improved patient prognosis when compared 
to traditional therapies. Nonetheless, the correct use of various antibodies in research and 
clinical setting is dependent on thorough validation of their properties.  
The rat immunisation with the mouse MCAM extracellular domain recombinant 
protein generated two stable hybridoma clones producing monoclonal antibodies that 
recognise mMCAMecd (chapter 3 of this thesis). These clones were renamed mMCAM10 and 
mMCAM66, for clones 10-2-1 and 66-11-5 respectively. 
Monoclonal antibodies mMCAM10 and 66 were evaluated for their use in a variety of 
immunostaining techniques using cells expressing recombinant full-length mouse MCAM and 
endogenous mouse MCAM expressed on the cell surface. Testing the antibodies by Western 
blotting, flow cytometry, immunofluorescence and immunohistochemistry indicated their 
utility in a diverse range of in vitro techniques. Epitope mapping and epitope competition 
assays showed to which part of the MCAM protein the antibodies bind, and whether the 
binding epitopes are distinct between these two antibodies. Antibodies were injected into the 
tumour bearing mice to examine the antibody binding properties in vivo. The knowledge of 
the distribution of antibodies in mouse healthy tissue and tumour is important for the 
therapeutic development of MCAM targeted cancer therapies. Finally, the variable region of 
the mMCAM10 was sequenced and cloned into the TOPO vector in order to be able to use it 









4.2 Generation of cells with stable expression of mMCAMfl-FLAG 
In order to characterise monoclonal antibodies for their use in techniques such as cell 
immunostaining or flow cytometry, a cell line expressing membrane mouse MCAM was 
generated. Lentiviral vector pWPI (containing an EMCV IRES sequence between a transgene 
cloning site and a GFP marker) was used to clone in the full-length mMCAM with a C-terminal 
FLAG tag (mMCAMfl-FLAG). The construct contained a signal peptide to permit cell surface 
expression. The GFP marker in the vector made it easier to visualise transduced cells. 
HEK293T cells were then transduced with pWPI (empty vector) or mMCAMfl-FLAG. 
The expression of mMCAMfl-FLAG was examined by Western blotting. Cells were lysed, and 
total protein separated in an SDS-polyacrylamide gel and transferred to a PVDF membrane. 
Proteins were blotted with commercial rat anti-mouse MCAM antibody (MAB7718, R&D) and 
anti-FLAG antibody (ab49763, Abcam). mMCAMfl-FLAG was successfully expressed by 
transduced HEK293T cells (Figure 4.1 A). 
 The expression of mMCAM on the surface of these cells was then examined by flow 
cytometry using anti-mouse MCAM antibody (MAB7718) (10 µg/ml) and Alexa Fluor® 546 
anti-rat IgG secondary antibody (1:100). The green fluorescence (FITC) gate was set using 
untransduced HEK293T cells (GFP negative population). Control rat IgG (R&D) and secondary 
was used to set the gate for red fluorescence (PE) negative population on pWPI cells. The red 
and green fluorescence channels were compensated using Summit software. Transduced 
HEK293T cells were first gated for GFP positive cells (FITC+ cells), and then examined for 
MCAM expression (PE+ cells). GFP-positive mMCAMfl-FLAG cells were over 99% positive for 









Figure 4.1 Expression of MCAM by mMCAMfl-FLAG (mM-FL) and pWPI (ctrl) transduced HEK293T 
cells. (A) Western blot of cell lysates from the HEK293T cells transfected with empty pWPI vector (ctrl) 
and mMCAMfl-FLAG (mM-FL) blotted with anti-mouse MCAM (α-mMCAM), anti-FLAG (α-FLAG) and 
anti-tubulin antibody (α-tubulin) (B) Flow cytometry of pWPI and mMCAMfl-FLAG cells incubated with 
anti-mMCAM antibody (MAB7718 in grey) or control rat IgG (IgG in blue). Gates were set for GFP 
positive cells GFP(+), and the mouse MCAM expression was detected via red fluorescence PE(+), 








4.3 Expression of endogenous mouse MCAM in mouse endothelial cell lines 
and the RENCA carcinoma cell line  
Mouse cell lines expressing endogenous mouse MCAM protein are of great use for 
characterisation of novel monoclonal antibodies. Two different mouse endothelial cell lines 
were tested for the expression of mMCAM: bENDs (murine brain derived transformed 
endothelial cells) and sENDs (murine skin derived transformed endothelial cells). Mouse 
RENCA tumour cell line is a murine model of renal cell carcinoma used to induce tumours in 
vivo. This cell line was tested for MCAM expression in order to confirm that MCAM is not 
expressed on the tumour cells.  
Cells of all three cell lines were lysed and total protein run on an SDS-polyacrylamide 
gel and transferred to a PVDF membrane. Western blot with anti-mMCAM (MAB7718) 
antibody showed high expression of mMCAM on bENDs, a lower expression on sENDs, and no 
expression on RENCA cells (Figure 4.2 A). Due to the higher expression of mouse MCAM on 
bENDs these cells were used in further validations of monoclonal antibodies described in this 
chapter.  
Flow cytometry with MAB7718 on bENDs further confirmed the expression of mouse 
MCAM (Figure 4.2 B). Cells were gated for a single cell population, and a PE negative 
population using unstained bENDs. Rat IgG control was used as a negative control. Over 90% 
















Figure 4.2 Expression of MCAM by mouse endothelial cell lines bENDs and sENDs, and RENCA mouse 
tumour cell line. A) Western blot of cell lysates from bEND, sEND and RENCA cells with anti-mouse 
MCAM (α-mMCAM) and anti-tubulin (α-tubulin). B) Flow cytometry of bEND cells incubated for 1 h 
with anti-mouse MCAM antibody (MAB7718 in grey) or control rat IgG (IgG in blue). MCAM expression 
was detected by red fluorescence PE(+). Numbers in the flow cytometry histograms represent the 









4.4 Analysis of mMCAM10 and 66 by flow cytometry 
Chapter 3 described the generation of two stable hybridoma cell clones generated by 
fusion of rat splenocytes and mouse myeloma cell line: mMCAM10 and mMCAM66. 
Supernatants from the stable hybridoma cells were used in early stages of validation of these 
antibodies after being provided by Biogenes. bENDs and HEK293T cells transduced with 
mMCAMfl-FLAG and pWPI plasmid were used to validate the new monoclonal antibodies by 
flow cytometry. Cells were incubated with undiluted supernatants from hybridoma clones 
mMCAM10 and 66 or with the rat IgG control (at 10 μg/ml) for 1 h at 4 °C. The cells were 
washed and incubated with the anti-rat secondary antibody conjugated to Alexa Fluor® 546 
(1:100) and analysed by flow cytometry. Monoclonal antibodies mMCAM10 and 66 were able 
to immunostain endogenous mouse MCAM on bEND cells (>93% of positive cells, for both) 
and recombinant mMCAMfl-FLAG protein expressed by HEK293T cells (>99% of positive cells, 










Figure 4.3 Analysis of monoclonal antibodies mMCAM10 and 66 by flow cytometry. bEND and 
HEK293T cells expressing mMCAMfl-FLAG or pWPI were used to test the antibodies reactivity in flow 
cytometry. The cells were detached from plates and incubated with hybridoma supernatants from 
clones mMCAM10 and 66 (10 and 66, in grey) or control rat IgG (IgG in blue). Transduced HEK293T 
cells were first gated for GFP expression. MCAM recognition was analysed by red fluorescence PE(+). 









4.5 Immunoprecipitation of mouse MCAM protein using mMCAM10 and 66  
To determine if the antibodies mMCAM10 and 66 can bind and extract native mMCAM 
protein from cell lysates, an immunoprecipitation experiment was performed. bEND cells 
were lysed using 1% NP-40 lysis buffer, and the lysates incubated with washed protein G beads 
and 1 μg/ml of rat IgG isotype control to prevent non-specific binding of proteins. Beads were 
removed by centrifugation and the lysates incubated overnight at 4 °C with purified 
monoclonal antibodies (mMCAM10, mMCAM66, MAB7718: commercial anti-mMCAM) or rat 
IgG control at a concentration of 2 μg/ml. Protein G beads were added to the lysates and 
incubated for 1 h at 4 °C. The beads were spun down, the supernatants collected, and beads 
washed 4 times. The lysate sampled before incubation with beads (bEND before beads), 
supernatants after incubation with beads (bEND lysates after beads) and protein G beads after 
IP (bEND lysate IP Protein G beads) were boiled in reducing protein loading buffer and run on 
an SDS-polyacrylamide gel. Purified monoclonal antibodies mMCAM10 and 66 were both able 
to immunoprecipitate mMCAM protein from the bEND cell lysates, although not in a great 
extent. Pull-down of the mMCAM protein was confirmed by Western blotting with polyclonal 
anti-mouse MCAM (AF6106, R&D) (Figure 4.4). Commercial monoclonal antibody MAB7718 
(MAB) bound mMCAM to a lesser extent than antibodies mMCAM10 and 66, and there was 
no pull down with the control rat IgG. However, despite high concentrations of antibodies 
protein signal in the lysates after beads stayed similar to the signal in the lysates before 









Figure 4.4 Immunoprecipitation of mouse MCAM with mMCAM10 and 66. Monoclonal antibodies 
mMCAM10, mMCAM66, MAB7718 (MAB) and rat IgG control (IgG) were used to immunoprecipitate 
mouse MCAM from bEND cell lysate (bEND before beads). Lysates were pre-cleared with rat IgG and 
protein G beads to remove unspecific binding. The lysates were then incubated with individual 
antibodies (2 μg/ml) over night and then for 1 h with Protein G beads. The beads (bEND lysate IP 
protein G beads) and the supernatants after the beads (bEND lysate after beads) were loaded on the 









4.6 Analysis of mMCAM10 and 66 by immunofluorescence staining of PFA 
fixed cells 
Immunofluorescence staining was used to determine if antibodies mMCAM10 and 66 
stain paraformaldehyde (PFA) fixed cells on coverslips. bENDs and HEK293T cells transduced 
with mMCAMfl-FLAG or pWPI vector were seeded onto glass coverslips and cultured for 2 
days. The cells were fixed on coverslips with 4% (w/v) PFA and incubated for 1 h at room 
temperature with undiluted supernatants of individual hybridoma clones mMCAM10 and 
mMCAM66, or with the rat IgG control (10 μg/ml). After washing with PBS, cells were 
incubated for 1 h in the dark with secondary anti-rat antibody conjugated to Alexa Fluor® 546 
(1:200). The cells on coverslips were then washed and mounted onto DAPI-containing 
mounting media on glass slides and imaged. Immunofluorescence staining with supernatants 
from clones mMCAM10 and mMCAM66 showed MCAM expression on the cell surface and in 
the cytoplasm of both bENDs and HEK293T with mMCAMfl-FLAG (Figure 4.5 A and B). The 
same staining pattern was observed with the commercial anti-mMCAM antibody (MAB7718) 
(data not shown).  
Antibodies did not stain pWPI transduced HEK293T cells (Figure 4.5 B), and no staining 




















Figure 4.5 Immunofluorescence staining of PFA-fixed cells using mMCAM10 and 66. A) Mouse 
endothelial cell line bEND and B) mMCAMfl-FLAG or pWPI transduced HEK293T cells (expressing GFP) 
were fixed on coverslips using 4% PFA and stained with the monoclonal antibodies mMCAM10 (10-
MCAM) and mMCAM66 (66-MCAM), or with the rat IgG negative control (IgG-MCAM). Nucleus was 
stained with DAPI (DAPI). The last image in a row is a merge between DAPI (blue), MCAM (red) and 








4.7 Analysis of mMCAM10 and 66 by immunofluorescence staining of frozen 
cell sections 
To investigate if antibodies mMCAM10 and 66 stain frozen sections, agarose 
embedded frozen cell blocks were prepared. HEK293T cells transduced with mMCAMfl-FLAG 
and pWPI were embedded in low melting agarose blocks and snap frozen in OCT freezing 
media. Cell-blocks were processed and sectioned. Slides were thawed before the experiment 
and fixed in acetone at -20 °C. Slides were then incubated with undiluted supernatants of 
individual hybridoma clones mMCAM10 and 66, or rat IgG control (10 μg/ml) for 1h at room 
temperature. The slides were washed with PBS and incubated for 1 h in the dark with 
secondary anti-rat antibody conjugated to Alexa Fluor® 647 (1:200) and mounted in DAPI-
containing medium for imaging. 
Both monoclonal antibodies mMCAM10 and 66 were able to stain the frozen 
embedded HEK293T cells expressing mouse MCAM but did not stain the pWPI transduced 
HEK293T cells. The control rat IgG did not stain the cells (Figure 4.6). The staining pattern was 
seen in the cell membrane and lightly in the cytoplasm of cells, corresponding to the staining 









Figure 4.6 Frozen cells sections immunofluorescence staining with mMCAM10 and 66. mMCAMfl-
FLAG or pWPI transduced HEK293T cells (expressing GFP) were embedded in low melting agarose, snap 
frozen and sectioned for immunostaining with undiluted hybridoma supernatants mMCAM10 (10-
MCAM) and 66 (66-MCAM), or with the rat IgG control at 10 μg/ml (IgG-MCAM). The nucleus was 
stained with DAPI (DAPI). The fourth image in a row is a merge between DAPI (blue), GFP (green) and 








4.8 Analysis of mMCAM10 and 66 by immunocytochemical staining of 
formalin fixed paraffin embedded cells 
To examine whether the antibodies mMCAM10 and 66 can stain formalin fixed 
paraffin embedded tissue sections, paraffin embedded agarose cell blocks were used. 
HEK293T cells transduced with mMCAMfl-FLAG or pWPI were embedded in low melting 
agarose blocks and fixed with formalin. Fixed agarose cell blocks were then embedded in 
paraffin and sectioned. Slides were subjected to two types of antigen retrieval: (i) the pH 6 
sodium citrate based and (ii) pH 9 Tris based antigen retrieval. Slides were then incubated with 
undiluted supernatants from mMCAM10 and 66, or rat IgG control at 10 μg/ml concentration 
for 1h at room temperature. The slides were washed with PBS and incubated for 1 h with 
secondary anti-rat antibody conjugated to HRP (1:100).  
Monoclonal antibodies mMCAM10 and 66 both stained formalin fixed paraffin 
embedded HEK293T cells expressing mouse MCAM but did not stain pWPI transduced 
HEK293T cells (Figure 4.7). The negative control rat IgG did not stain the cells. Both antigen 
retrievals (citrate buffer pH 6 and with Tris buffer pH 9) were compatible for staining with 










Figure 4.7 Immunocytochemical staining of formalin fixed paraffin embedded sections with 
mMCAM10 and 66. HEK293T cells expressing mMCAMfl-FLAG and pWPI were embedded in the low 
melting agarose blocks, fixed in formalin, embedded in paraffin and sectioned. Antigen retrieval was 
done in two different ways, using sodium citrate pH 6, and Tris based pH 9 with boiling in microwave 
for 15 min both. Immunocytochemistry staining was performed on slides with undiluted hybridoma 








4.9 Generation of deletion constructs of the mouse MCAM extracellular 
domain 
The identification of the binding epitope is useful for monoclonal antibody targeted 
therapies. To determine which extracellular domain of antibodies mMCAM10 and 66 bind, 
deletion constructs of the extracellular domain of mMCAM were generated. The deletion PCR 
inserts were cloned into the pIg vector at EcoRI and NotI restriction sites using T4 DNA ligase 
(as described in materials and methods). DNA inserts were designed in such way that selected 
domains of the extracellular part of MCAM were deleted. The first deletion construct (D1) had 
domain C2’’ deleted, the second construct (D2) had C2’’ and C2’ domains deleted and finally, 
the third construct (D3) had the C2’’, C2’ and C2 domains deleted. This is schematically shown 
in Figure 4.8 A. All constructs were designed to contain a signal peptide for secretion and a 
human Fc tag on the C-terminal end for detection and affinity purification.  
HEK293T cells were transfected with the deletion constructs. Cell supernatants were 
collected 2 days later, and cells lysed. Supernatants and lysates were run on the gel under 
reducing and non-reducing conditions. Proteins were transferred to a PVDF membrane and 
blotted with anti-Fc antibody (Sigma). Cells all expressed proteins (as shown in the cell lysate 
Western blot), however the D2 construct was not secreted into the cell medium (Figure 4.8 
B). This was possibly due to inefficient folding of the protein. For that reason, cell lysates were 












Figure 4.8 Design and expression of mouse MCAM extracellular domain deletion constructs. A) 
Schematic image of deletion constructs with native mouse MCAM on the left and mMCAMecd-Fc and 
deletion constructs D1, D2 and D3 on the right; the V1, V2, C2, C2’ and C2’’ are the domains of the 
mouse MCAM extracellular domain. B) Western blot of cell lysates and conditioned cell media of 
HEK293T cells producing the deletion constructs D1, D2 and D3; pIg-transfected HEK293T cell were 
used as a negative control (-). Proteins were loaded under reducing and non-reducing conditions to 








4.10 Epitope mapping of antibodies mMCAM10 and 66  
HEK293T cells transfected with the deletion constructs were lysed and total protein 
loaded on an SDS-polyacrylamide gel under reducing and non-reducing conditions. Proteins 
were transferred to a PVDF membrane and blotted with anti-Fc antibody (Sigma), mMCAM10 
and 66 hybridoma supernatants and commercial MAB7718 anti-mMCAM monoclonal 
antibody.  
Both mMCAM10 and 66 recognised the full-length extracellular domain and the 
deletion construct D1 without the C2’’ domain in the non-reducing conditions. However, they 
did not recognise the D2 and D3 (Figure 4.9). 
Both antibodies mMCAM10 and 66 recognised all the constructs in the reducing 
conditions showing that the epitope is present in all these forms of the protein, and that the 
antibodies can recognise the linearized epitope. The commercial MAB7718 failed to recognise 















Figure 4.9 Epitope mapping of monoclonal antibodies mMCAM10 and 66 on deletion constructs of 
mMCAMecd. Cell lysates from deletion constructs D1, D2, D3, control pIg cells and recombinant 
mMCAMecd-Fc were loaded on the gel in A) reducing conditions and B) non-reducing conditions and 
the proteins blotted with anti-human Fc antibody (α-Fc), hybridoma supernatants mMCAM10 and 66 






































4.11 Competition binding of mMCAM10 and 66 studied by flow cytometry 
A flow cytometry competition assay was used to examine if the binding epitopes of 
monoclonal antibodies mMCAM10 and 66 are overlapping or distinct. Monoclonal antibody 
mMCAM10 was conjugated with fluorescent label Alexa Fluor™ 488. bENDs were detached 
from plates, washed and spun down. Cells were first incubated with blocking antibody at 100 
μg/ml (monoclonal antibodies mMCAM10 and 66, or control rat IgG) for 2 h at 4 °C to block 
the epitope on the extracellular domain of mouse MCAM. Following this, the cells were 
washed 2 times with flow cytometry buffer and incubated with Alexa Fluor™ 488-conjugated 
mMCAM10 antibody (10-488) at a concentration of 100 μg/ml for 1 h. Flow cytometry buffer 
was added, and cells were tested for green fluorescent labelling by flow cytometry.  
The gates were set for single cells and FITC negative cells using unblocked and 
unlabelled bENDs. Cells incubated only with antibody 10-Alexa Fluor™ 488 were around 49.6% 
FITC+. The cells blocked with control rat IgG and then labelled with 10-488 were 47.6% positive 
for FITC staining. The cells blocked with antibody 10 and 66 had a reduced FITC labelling with 
9.87% and 14.5% of cells positive, respectively Figure 4.10. This showed that the antibodies 
mMCAM10 and 66 both blocked binding of the labelled antibody 10-Alexa Fluor™ 488 in a 













Figure 4.10 Epitope binding competition assay of mMCAM10 and 66. bENDs were blocked with either 
rat IgG control (IgG), mMCAM10 (10) or mMCAM66 (66) monoclonal antibody and then 
immunostained with Alexa Fluor™ 488-conjugated mMCAM10 antibody (10-488). The percentage of 
green cells (FITC+) was checked by flow cytometry. The cells were compared between each other and 
to negative control bEND cells that were not blocked or stained with any antibody, and to positive 
























4.12 Study of mMCAM10 and 66 in IHC staining of formalin fixed paraffin 
embedded mouse tissue 
To investigate whether antibodies mMCAM10 and 66 can stain mouse MCAM 
expressed in the native form in the mouse tissue, paraffin embedded sections of mouse 
RENCA tumour were examined. RENCA cells do not express MCAM (as shown in Figure 4.2), 
however, MCAM is expressed on the blood vessels of mouse RENCA tumour model. The 
sections were prepared as described in section 4.8. Sections were then subjected to antigen 
retrieval with sodium citrate pH 6, as this worked better on immunocytochemistry (section 
4.8). The slides were blocked and probed with purified monoclonal antibodies mMCAM10, 66 
and negative control rat IgG at a concentration of 15 μg/ml and incubated for 1 h at room 
temperature. The slides were washed with PBS and probed with HRP conjugated anti-rat 
antibody (1:100) for 45 min at room temperature. The reaction was developed for 5 min and 
slides stained with haematoxylin.  
Staining of blood vessels in RENCA sections was seen only with the monoclonal 
antibody mMCAM10 and not with 66, or control IgG. Three representative images for each 
antibody are shown in Figure 4.10.  
The antibody mMCAM10 was then tested for staining of blood vessels of healthy 
mouse organs: brain, heart, kidney, liver and lung. No staining of blood vessels was obtained, 
showing that antibody mMCAM10 recognises the tumour blood vessels but not the 












Figure 4.10 Immunohistochemical staining of formalin fixed and paraffin embedded RENCA tumour 
sections with monoclonal antibodies mMCAM10 (10), mMCAM66 (66) and control rat IgG (IgG). 
RENCA tumours were taken from tumour bearing mice, fixed in formalin and embedded in paraffin. 













Figure 4.11 Immunohistochemical staining of paraffin embedded mouse healthy organs and RENCA 
sections with monoclonal antibody mMCAM10. Brain, heart, kidney, liver, lung and RENCA tumour 
were taken from tumour bearing mice, fixed in formalin and embedded in paraffin. Sections were 









4.13 In vivo localisation of mMCAM10 in tissue of tumour bearing mice 
Knowledge of distribution of monoclonal antibodies mMCAM10 and 66 after delivery 
to mice would provide information crucial for the future development of targeted therapies 
using these antibodies. In order to investigate whether these antibodies specifically localise 
to the tumour blood vessels a RENCA mouse tumour model was used. 
Cultured RENCA cells were harvested and implanted subcutaneously in mice. Tumours 
were monitored until they reached 1 cm3. The purified monoclonal antibodies mMCAM10 and 
66 were dialysed against PBS and filter sterilised. 20 μg of each antibody was injected into the 
tail vein. Mice were monitored for 1 h and then culled. The organs were taken, snap-frozen in 
OCT freezing medium, and sectioned. 
The frozen sections were thawed at room temperature and fixed in acetone at -20 °C. 
Slides were blocked with 100 µl of 2.5% (v/v) horse serum and incubated with the AlexaFluor® 
488 conjugated anti-rat IgG (1:200) secondary antibody for 1 h at room temperature in the 
dark. The antibody localisation into the different organs and the tumour vessels was analysed 
by green fluorescence staining of the tissues. Antibody mMCAM66 failed to localise in any 










Figure 4.12 Localisation of the antibody mMCAM10 to the tumour blood vessels in mice. Tumour 
bearing mice were injected with 20 μg of monoclonal antibody intravenously. The mice were culled 1 
h later and the organs and tumour snap frozen in OCT medium. The tissue sections were probed with 
secondary anti-rat antibody conjugated to Alexa Fluor® 488 to determine the localisation of injected 
antibody in the tissue (anti-rat IgG) and mounted in DAPI mounting media for nuclei staining (DAPI). 








4.14 Sequencing of the variable regions of mMCAM10 and 66 
To characterise the variable regions of the antibodies mMCAM10 and 66, cloning and 
sequencing was carried out. Sequences of variable regions can be used in protein engineering, 
such as switching of a constant region to different isotype or a different species 
immunoglobulin backbone, or engineering CAR-T cell receptors.  
Sequencing variable regions of heavy and light chains of the mMCAM10 and 66 
requires the knowledge of the isotype in order to design correct primers for the RACE PCR 
reaction (Figure 4.13). The Ig Isotyping Rat Uncoated ELISA Kit (Invitrogen) was used to define 
the isotype of antibodies mMCAM10 and 66. ELISA plate provided in the kit was coated with 
capture antibodies specific for individual rat heavy and light chains (IgG1, IgG2a, IgG2b and 
IgG2c heavy chains; and kappa and lambda light chains). The plate was treated with blocking 
buffer and probed with hybridoma supernatants from clone mMCAM10 and 66. The ELISA 










Figure 4.13 A schematic image of the RACE PCR reaction used to amplify the heavy and light chain 
variable regions of antibodies. The procedure consists of mRNA extraction from the hybridoma cells, 
reverse transcription and generation of cDNA (RT), addition of the poly-C tail to the cDNA (Poly-C 
tailing) and 2 PCR reactions (PCR1 and PCR2) using specific primers for the poly-C end (Poly-G-anchor 
and Anchor primer) and for the constant regions of the heavy and light chains (IgG1/kappa specific 











Figure 4.14 Monoclonal antibody isotype determination by ELISA. The ELISA plate was coated with 
antibodies to different IgG heavy chains (IgG1, IgG2a, IgG2b, IgG2c) and light chains (kappa, lambda) 
of rat antibodies. This was probed with supernatants of hybridoma mMCAM10 and 66. The absorbance 
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To determine variable region sequences, hybridoma cells were lysed and mRNA 
extracted. The cDNA was then transcribed from the mRNA. Poly-C tail was added to the cDNA 
3’ end using terminal transferase, and the buffer exchanged to nuclease free H2O. The DNA 
was then used in the first PCR using a primer for the poly-C tail (Poly-G-anchor) and 
IgG1/kappa constant region specific outer primer. The PCR product from this reaction was 
then used as a template for the second PCR reaction using Anchor primer and IgG1/kappa 
constant region specific inner primer (as shown in the schematic image Figure 4.13). 
The final PCR product was then cloned into the TOPO vector and transformed into 
bacterial cells. The plasmids from single colonies were screened for the presence of the PCR 
insert using colony PCR (with Anchor primer and IgG1/kappa specific inner primer) and 
restriction digest.  
The sequence of the heavy and light chain of antibody mMCAM10 was confirmed as a 
variable region of a rat monoclonal antibody using the online program IMGT/V-QUEST 143 
(Table 4.1 and Table 4.2). However, sequencing of antibody 66 variable region failed at the 
step of TOPO cloning. No colonies were screened as positive for the PCR of the insert in the 
TOPO vector, or restriction digest.  
The program identified these regions as CDR regions of the antibody: 























Table 4.1 Comparison of the mMCAM10 heavy chain variable sequence to the online rat 
immunoglobulin database. 
Result summary:  Productive IGH rearranged sequence: (no stop codon and in-frame junction) 




= 95.14% (274/288 nt) 
J-GENE and allele Ratnor IGHJ2*01 F score = 205 
identity = 90.00% (45/50 
nt) 
D-GENE and allele by 
IMGT/JunctionAnalysis 
Ratnor IGHD1-
1*01 F D-REGION is in reading frame 3 
FR-IMGT lengths, CDR-IMGT lengths 
and AA JUNCTION [25.17.38.11] [8.8.12] CTTDRNYSAYFDSW 
 
 
Table 4.2 Comparison of the mMCAM10 light chain variable sequence to the online rat 
immunoglobulin database. 
Result summary: Productive IGK rearranged sequence: (no stop codon and in-frame junction) 
V-GENE and allele Ratnor IGKV1S27*01 F score = 1402 
identity 
= 97.62% (287/294 nt) 
J-GENE and allele Ratnor IGKJ1*01 F score = 175 
identity = 100.00% 
(35/35 nt) 
FR-IMGT lengths, CDR-IMGT 









4.15 Discussion  
This chapter describes the generation of two stable hybridoma cell clones, mMCAM10 
and mMCAM66, and their biochemically characterisation. Screening of positive hybridoma 
clones was performed by ELISA on recombinant full length mMCAM extracellular domain in 
order to identify antibodies to the native protein. mMCAM10 and 66, could detect mMCAM 
on cells via flow cytometry and by staining PFA fixed cells on coverslips. These techniques are 
useful in cell biology when monitoring expression of protein in various conditions, such as 
protein knock down, or detecting expression changes in response to treatment. Thus, siRNA 
silencing of mouse MCAM gene would be a useful indicator of sensitivity of these antibodies 
and is yet to be done. Furthermore, both antibodies immunprecipitated native mMCAM 
protein. Using this technique can further investigate MCAM binding partners by protein pull 
down and performing mass spectrometry analysis. The mMCAM10 and 66 detected mMCAM 
by immunocytochemistry and immunofluorescence staining of agarose embedded cells 
overexpressing mMCAM. It would be useful to establish the lowest antibody concentration 
that can be used in this technique in order to titrate down the use of the antibodies.  
MCAM extracellular domain deletion constructs D1, D2 and D3 were used in order to 
investigate the binding domain of mMCAM10 and 66. Western blot analysis showed the 
recognition of a linear epitope present in reduced conditions in all three deletion constructs. 
However, the D2 and D3 deletion constructs were not recognised in the non-reduced form, 
possibly due to conformational changes. It is possible that the important domain for 
stabilization of the epitope is missing from these two constructs and the protein is folding in 
such a way that the epitope is hidden. Thus, the results show that the possible binding site of 








recognisable in both non-reducing and reducing conditions. Commercial rat monoclonal 
antibody to mouse MCAM recognised only the non-reduced form of deletion construct D1, 
but not D2 or D3, and did not recognise any of the recombinant mMCAM on the reducing gel.  
Competition flow cytometry assay showed that the two antibodies compete for the 
same or a similar epitope. Given the results observed in mice we assumed that the antibodies 
do not recognise the rat MCAM and so, the possible binding site of the antibodies could be 
the amino acids that are different between the rat and mouse sequence in the V1 or V2 
domain (The sequence difference can be seen in Figure 3.8). Inserting point mutations would 
help determine the exact place to which the antibodies are binding. Furthermore, in this study 
the competition assay was performed in one way, by blocking with antibody mMCAM66 and 
then detecting with antibody mMCAM10, and so the other way around would possibly better 
show the binding differences between these two antibodies.  
Monoclonal antibody ME-9F1 was previously shown to recognize mouse MCAM that 
seemed to be present on all vessels in mouse tissue 144. In contrast, the mMCAM10 antibody 
detects only RENCA tumour vessels, but not vessels in healthy tissues when studied by 
immunohistochemistry. Similarly, antibodies towards human MCAM show a different 
spectrum of tissue recognition depending on the antibody. Several papers showed that the 
carbohydrates, which constitute 35% of the MCAM molecular weight, vary between different 
cell types and tissues 60,93. Furthermore, MCAM forms dimers and binds different proteins in 
different environments. Thus, epitopes exposed on MCAM in one tissue may be hidden in 
another. 
In order to use a specific antibody for therapeutic purposes it is essential to determine 








localisation to the tumour vasculature of RENCA tumours within 1 h post injection, while only 
faint or no staining was observed in the examined healthy tissue. In contrast ME-9F1 localises 
to the healthy tissue when injected intravenously 144. Furthermore, MCAM on healthy tissue 
had to be pre-blocked by un-labelled antibody in order for the radionuclide labelled ME-9F1 
antibody to localise to tumour blood vessels only. 
This study is a starting point for further investigation of mMCAM10 as a therapeutic 
agent. In order to be able to use this antibody in mice with a fully functional immune system, 
which is important to generate similar conditions to clinical tumours, the variable regions 
need to be cloned into the mouse immunoglobulin backbone. Several plasmids are available 
commercially and used routinely for this purpose. Furthermore, these sequences can be used 
to generate other types of immunotherapies such as modified CAR-T cells, engineered 
antibodies with bound cytotoxic drug or modified Fc portion. All of these are rapidly entering 
clinical trials and will form part of the future of antibody-based immunotherapies.  
In conclusion, work performed in this study resulted in characterisation of novel 
monoclonal antibodies against mouse MCAM and will enable the future use of these tools in 
research and assessment of MCAM potential as a target on tumour vasculature.  









5.1 Introduction  
MCAM is expressed on blood vessels of 90 % of RCC and its expression correlates with 
cancer stage 56. The importance of MCAM expression on tumour vasculature is however, 
poorly understood. RCC is a highly vascular tumour where angiogenesis aids progression and 
metastatic spread, and because of this targeting tumour angiogenesis has been a paradigm 
treatment approach for this cancer in the recent years 145. However, targeting VEGF pathway 
either by using receptor tyrosine kinase inhibitors or Bevacizumab still has not achieved 
complete response in metastatic disease 146. Soluble extracellular domains of cell surface 
proteins can act as scavengers or antagonists of pro-angiogenic factors and in this way block 
angiogenesis such as in the case of the soluble VEGFR-2 (flk-1) receptor trap 147. MCAM has a 
number of ligands which induce angiogenesis and associated signalling, including Netrin-1, 
VEGF and LAMA4 111,113. Thus, studying the effects of extracellular domain of human MCAM 
protein in angiogenesis assays could provide more information on the role of MCAM as well 
as create a base for new treatment opportunities for advanced and metastatic RCC. 
In order to investigate soluble MCAM in angiogenesis assays, the soluble extracellular 
domain of human MCAM was produced and purified with a human Fc fusion tag. The 
recombinant soluble protein was investigated in in vitro angiogenesis assays using HUVECs. 
Soluble MCAM showed blocking activity in three different endothelial cell network formation 
assays, cell migration and cell transmigration through a semipermeable membrane. The 









5.2 Production and purification of hMCAMecd-Fc recombinant protein 
To investigate whether the extracellular domain of MCAM has an effect on HUVECs in 
angiogenesis associated behaviour, such as migration, proliferation and tube formation, 
human MCAM extracellular domain was cloned with human Fc tag at the C-terminal end 
(Figure 5.1 A). Vector construction was performed as described in materials and methods: A 
PCR insert (hMCAMecd) was cloned into the pcDNA-Fc (pIg) vector using EcoRI and NotI 
restriction enzymes and T4 DNA ligase (hMCAMecd-Fc).  
HEK293T cells were transfected with hMCAMecd-Fc or with the empty pIg vector and 
cultured to confluence in complete DMEM, and then placed in Opti-MEM. The protein was 
successfully expressed by cells and secreted into the cell culture medium, as confirmed by 
Western blotting using anti-human Fc (Sigma) and anti-hMCAM antibodies (Sigma) (Figure 5.1 
B).  
The protein was next pulled-down from the conditioned Opti-MEM (collected 48h 
after addition to transfected cells) with protein A beads. The beads were run on an SDS-
polyacrylamide gel and protein stained with Coomassie blue. The hMCAMecd-Fc protein 
efficiently bound to the beads and was not degraded (Figure 5.1 C).  
Purification on a large scale was carried out from one litre of conditioned Opti-MEM 
obtained from ten 15 cm cell culture dishes. Opti-MEM was collected every third day over two 
weeks and then run through a Protein A column. The eluted protein was run on an SDS-
polyacrylamide gel and stained with Coomassie blue (Figure 5.1 D). The protein yield was >15 
mg/litre of media. The elution fractions were pooled and dialysed to exchange the elution 









Figure 5.1 Production and purification of hMCAMecd-Fc recombinant protein. A) Schematic image of 
the extracellular domain of hMCAM fused to the human Fc tag; B) Western blot of supernatants from 
the HEK293T cells transfected with empty pIg vector (ctrl) and hMCAMecd-Fc (hM-Fc) blotted with 
anti-human Fc antibody (α-Fc) and anti-hMCAM antibody (α-hMCAM); C) Coomassie blue staining of 
small scale protein pull down with Protein A beads from the hMCAMecd-Fc and pIg transfected 
HEK293T cell media (1 ml), 20 μl of beads were loaded on the gel, BSA standard in µg; D) Coomassie 
blue staining of large scale purification of hMCAMecd-Fc on a Protein A column, 1 μl of elution fractions 








5.3 Effects of hMCAMecd-Fc on endothelial cell tube formation in the 
fibroblast co-culture 3D assay 
Tube or network formation assays are one of the preferred assays to investigate 
effects of materials on angiogenesis. There exist different models of network formation assays 
in which cells are tested in a monoculture or co-culture with other cells involved in 
angiogenesis. Cells are usually seeded in different extracellular matrices either on top (2D) or 
inside the matrix (3D) 148. To examine if the recombinant hMCAMecd-Fc has an effect on 
network formation of endothelial cells, the 3D fibrin matrix co-culture with human dermal 
fibroblasts (HDFs) was carried out. This experiment was initially carried out by Aleksandra 
Korzystka using commercially obtained HUVECs (mixed cells from different donors) at a range 
of MCAM concentrations; and later confirmed by the author using HUVECs prepared form 
individual cords by our group at a concentration of MCAM at 200 μg/ml (1.54 μM). The 
experiment was repeated three times with three technical replicates for each condition and 
analysed using ImageJ angiogenesis plugin software. 
HUVECs were lentiviraly transduced with GFP prior to the assay in order to distinguish 
them from HDFs. HUVECs and HDFs were mixed in a ratio of 2:1 in the fibrin matrix. Cells were 
cultured for 10 days in complete EBM-2 medium containing the recombinant hMCAMecd-Fc 
or control Fc protein at different concentrations. Cells were monitored every day and medium 
changed every second day.  
The recombinant hMCAMecd-Fc protein at a concentration of 200 μg/ml (1.54 μM) 
had a significant effect on the cell tube formation as shown by decreasing total network 
length, number of meshes, nodes, and junctions when compared to the human Fc control 









Figure 5.2 Representative images of 3D co-culture tube formation assay. HUVECs (fluorescently 
labelled) and human dermal fibroblast cells were embedded in fibrin matrix and cultured in medium 
containing either control Fc protein or hMCAMecd-Fc at a concentration of 200 μg/ml. Images were 

















Figure 5.3 hMCAMecd-Fc inhibits HUVECs tube formation in 3D fibrin matrix co-culture. HUVECs and 
HDFs were assayed in 3D fibrin matrix co-culture tube formation assay; cells were seeded in the matrix 
and cultured for 10 days in medium containing either control Fc protein or hMCAMecd-Fc at the 
concentrations of 50, 100 and 200 μg/ml, after which cells were fixed and several aspects of tube 
formation analysed by ImageJ angiogenesis plugin (A, B, C, D). Three separate experiments with 
triplicates were taken into analysis. Error bars represent SEM. (Statistical test used: Two-way ANOVA, 








































































































5.4 Effects of hMCAMecd-Fc on endothelial cell tube formation in the 2D 
matrigel assay 
In order to confirm the effects found in the 3D co-culture assay (section 5.3), a second 
tube formation assay was used. Matrigel is a 2D monoculture angiogenesis tube formation 
assay. The effects of recombinant hMCAMecd-Fc on the co-culture could be because of the 
effects on human dermal fibroblast cells, thus monoculture assay was performed to eliminate 
that possibility. Cells were seeded on top of the matrigel matrix in 12 well plates and cultured 
in complete M199 with addition of recombinant protein hMCAMecd-Fc or control Fc (at 1.54 
μM). Cells were cultured for 24 h and live images taken every 6 h. Three experiments using 
HUVECs from distinct umbilical cords were analysed with 9 fields of view for each well. The 
ImageJ angiogenesis plugin software was used to calculate the parameters of endothelial cell 
network formation in each field of view. A paired t test showed significant reduction in 
number of meshes, nodes, junctions and total network length for hMCAMecd-Fc protein 
treated cells compared to human Fc treated ones (Figure 5.4 and Figure 5.5). The tube 
formation assay showed that hMCAMecd-Fc reduced the ability of HUVECs to form capillary 
like structures and networks when seeded on matrigel extracellular matrix components 
already at 6h post seeding for all the parameters. This confirmed results from fibrin matrix 3D 











Figure 5.4 Representative images of 2D matrigel tube formation assay. HUVECs were seeded onto 
matrigel and cultured for 24 h in medium containing either control Fc protein or hMCAMecd-Fc at a 

















Figure 5.5 hMCAMecd-Fc inhibit HUVECs tube formation in 2D matrigel mono-culture. HUVECs were 
seeded onto matrigel and cultured for 24 h in medium containing either control Fc protein or 
hMCAMecd-Fc at a concentration of 1.54 μM. Images were taken live at time-points 6, 12, 18 and 24 
h after seeding and several aspects of the tube formation analysed by ImageJ angiogenesis plugin. Nine 
fields of view per experiment were averaged and 3 experiments analysed. Error bars represent SEM. 















































































































5.5 Effects of hMCAMecd-Fc on EC tube formation in the fibroblast co-
culture 2D assay 
In order to further confirm an effect on angiogenesis, another tube formation co-
culture was performed. The 3D co-culture used premade fibrin matrix in which the cells were 
immersed, while the 2D co-culture took advantage of the fibroblast-secreted matrix. Here, 
HDFs were seeded and cultured for 5 days in order to form a monolayer on the bottom of the 
well and to secrete matrix proteins. HUVECs were seeded onto the fibroblast monolayer and 
cultured for 6 days, after which cells were fixed and immunostained with anti-human CD31 
(in order to visualise only the endothelial cells). The experiment was repeated with HUVECs 
from five distinct umbilical cords and whole wells analysed using ImageJ angiogenesis plugin. 
The recombinant hMCAMecd-Fc protein again significantly but modestly reduced the number 
of meshes, nodes, junctions and total network length when compared to human Fc control 
(Figure 5.6). The fact that recombinant hMCAMecd-Fc consistently reduced tube formation in 
















Figure 5.6 hMCAMecd-Fc protein inhibits tube formation of HUVECs in 2D fibroblast co-culture. 
HUVECs were seeded on the layer of confluent human dermal fibroblast cells and cultured for 6 days 
in the presence of control Fc protein and hMCAMecd-Fc protein at a concentration of 1.54 μM. Cells 
were fixed and stained with anti- human CD31 antibody for HUVEC visualisation. A) Representative 
images of endothelial cell network at day 6; B, C, D, E) Whole wells of five experiments with HUVECs 
from distinct cords were analysed using ImageJ angiogenesis plugin. Error bars represent SEM. 





































































5.6 Effects of hMCAMecd-Fc on HUVEC proliferation and cell cycle 
Proliferation of endothelial cells is an important component of angiogenesis. Tip cells 
migrate through the extracellular matrix attracted by pro-angiogenic signals from the 
environment while stalk cells proliferate to elongate the newly formed micro-vessels 149. In 
order to investigate the effect of recombinant MCAM extracellular domain on proliferation of 
HUVECs the CellTiter 96® Non-Radioactive Cell Proliferation Assay was used. HUVECs were 
seeded in 96 well plates and cultured in complete M199 medium (cM199), cM199 with 
addition of hMCAMecd-Fc, or cM199 with human Fc control protein (at a concentration of 
1.54 μM). Proliferation was measured at time-points of 24, 48 and 72 h using a commercial kit 
(materials and methods). HUVECs from three distinct umbilical cords were analysed, with 
three technical replicates for each time-point. Recombinant hMCAMecd-Fc protein did not 
affect the proliferation of HUVECs over the period of three days (Figure 5.7 A). 
The disruption of cell cycle can also affect angiogenesis processes. The cell cycle 
consists of G1 (Gap1), S (synthesis) and G2/M (gap2/mitosis) and was distinguished by the 
amount of DNA in cells stained by propidium iodide. HUVECs were cultured for 24 h in cM199 
medium, cM199 with hMCAMecd-Fc, or cM199 with human Fc control protein (at 1.54 μM), 
fixed and stained with propidium iodide. HUVECs from three distinct umbilical cords were 
analysed using flow cytometry. The percentages of cells in G1, S and G2 phases were 
unchanged in the presence of hMCAMecd-Fc or Fc control, when compared to untreated 















Figure 5.7 hMCAMecd-Fc does not have an effect on HUVECs proliferation and cell cycle. A) HUVECs 
were seeded in 96 well plates with addition of complete medium (ctrl), hMCAMecd-Fc or human Fc, 
at 1.54 μM. Cell proliferation was analysed at 24, 48 and 72 h after seeding using CellTiter 96® Non-
Radioactive Cell Proliferation Assay. Absorbance was measured at 570 nm. B) HUVECs were cultured 
for 24h in complete medium or with addition of hMCAMecd-Fc or human Fc at 1.54 μM. The fixed cells 
were stained with propidium iodide and analysed by flow cytometry. Percentage of cells in each phase 
was calculated for HUVECs from three distinct umbilical cords. For both figures experiments were 





















































5.7 Effects of hMCAMecd-Fc on endothelial cell migration in the scratch 
wound assay 
The blocking effect of MCAM recombinant protein in network formation assays could 
be due to an effect on cell migration. Cells need to migrate in order to reach other cells, 
connect to them and form a functional tube. Knock down of MCAM and some anti-MCAM 
antibodies have previously shown to impair HUVEC cell motility 102,111,113. In order to 
investigate if recombinant hMCAMecd-Fc has an effect on the cell migration the cell culture 
wound closure assay was used. HUVECs were seeded in a 96 well plate. After the cells reached 
confluence a wound was created in the cell monolayer and the detached cells removed by 
washing. The cell culture medium was replaced by the medium containing the recombinant 
hMCAMecd-Fc protein or the control Fc protein at a concentration of 1.54 μM. Cells were 
monitored over 24 h and live images taken at 6, 12, 18 and 24 h. Images were analysed for the 
percentage of wound closure compared to the wound area at time-point 0 h and statistical 
analysis performed with GraphPad Prism software. Three experiments with HUVECs from 
distinct umbilical cords were used with three technical replicates for each. No significant 
difference was observed between the two groups at 18 or 24 h possibly due to some HUVECs 
being able to close the wound in a faster manner, however migration was slightly but 
significantly reduced in the first 12 hours (Figure 5.8). hMCAMecd-Fc protein effects migration 



















Figure 5.8 hMCAMecd-Fc inhibits endothelial cell migration. HUVECs were cultured to confluence in 
96 well plates. Wound in the monolayer was made and cells cultured in the presence of control Fc 
protein and hMCAMecd-Fc protein at a concentration of 1.54 μM. Cells were monitored over 24 h 
and images taken live at time-points 0, 6, 12, 18 and 24 h after scratching and percentage of wound 
closure analysed using ImageJ. Three experiments with three technical replicates were analysed. 
Error bars represent SEM. (statistic test used: Paired t test, * p<0.05) 
 
























5.8 Effects of hMCAMecd-Fc on endothelial cell transmigration 
MCAM was shown to be involved both in lymphocyte and tumour cell transmigration 
through the endothelium 99,150. In order to investigate the effects of recombinant hMCAMecd-
Fc protein on cell chemotaxis and transmigration, a HUVEC trans-well cell migration assay was 
carried out.  
HUVECs were ´starved´ in serum free and brain extract free M199 medium for 1 h 
before seeding to the upper side of the trans-well insert in the same medium. The trans-well 
insert was then placed in the cell culture 24 well plate containing complete M199 medium. 
Recombinant hMCAMecd-Fc or control human Fc were added to the upper side of the trans-
well together with the cells (at a concentration of 1.54 μM). The cells were left to migrate 
through the membrane in response to FCS and brain extract for 5 h. After this, cells were fixed, 
and nuclei of migrated cells stained and counted. Nine fields of view per insert were analysed 
for HUVECs from three distinct umbilical cords. The counted cells were averaged per field of 
view for each experiment. hMCAMecd-Fc protein significantly impaired ability of the 
endothelial cells to migrate through the membrane towards growth factors from the FCS and 




















Figure 5.9 hMCAMecd-Fc inhibits HUVEC chemotactic transmigration. HUVECs were starved for 1 h 
in serum and brain extract free media. HUVECs were then seeded on the upper side of trans-well insert 
in the same serum free media, and the inserts placed in the wells containing complete media. 
Recombinant protein hMCAMecd-Fc and control Fc were added to the inserts with cells at 1.54 μM 
and the cells left to migrate towards the bottom part for 5 h. A) representative images of migrated 
cells after 5h; B) Nuclei of migrated cells were stained and counted in 9 fields of view per experiment. 
Average number of cells per field of view were calculated and paired for each experiment. Error bars 



































This chapter showed recombinant hMCAMecd-Fc protein significantly impaired 
HUVECs cell migration, transmigration and tube formation when compared to the Fc treated 
control at a concentration of 1.54 μM using in vitro angiogenesis assays. The recombinant 
hMCAMecd-Fc protein however, had no effect on HUVEC cell proliferation or cell cycle.  
MCAM has previously been reported to play a role in several cell processes that are 
important for angiogenesis. For example, knock down of MCAM by siRNA had a negative effect 
on cell proliferation, adhesion, migration and netrin-1 induced tube formation in HUVECs 
matrigel assay 102,111. Similarly, endothelial cell sprouting, migration and tube formation as 
well as tumour angiogenesis are impaired in the endothelial MCAM knock-out mice 151. 
Several antibodies to MCAM have also shown anti-angiogenic activity 108,111,152,153. One 
antibody to human MCAM (ABX-MA1) reduced HUVECs tube formation after binding MCAM 
on the cell surface 103 possibly by blocking its interaction with ligands or by altering its 
signalling. A possible mode of action of the recombinant hMCAMecd-Fc could be binding of 
MCAM ligands. MCAM was shown to bind laminin411 and laminin421 (components of 
extracellular matrices), and in this way promote endothelial cell adhesion and migration 109,110. 
Recombinant hMCAMecd-Fc could be binding to its extracellular matrix ligands and thus 
restrict the binding of cell surface MCAM on HUVECs and in this way inhibit the ability of 
HUVECs to migrate on or through the matrix to form endothelial cell network. However, other 
possibilities such as hMCAMecd-Fc binding a ligand on HUVECs cannot be excluded. Future 
experiments investigating recombinant hMCAMecd localisation and binding in these assays 








In contrast with our data, recent publication using soluble recombinant MCAM 
extracellular domain protein showed pro-angiogenic effects on HUVECs and endothelial 
progenitor cells (EPCs). Stalin et al. (2016) showed that treating HUVECs with 100 ng/ml of 
soluble MCAMecd-myc had similar effects as 100 ng/ml of VEGF; it induced HUVECs 
proliferation and tumour vascularization in mice 106. Furthermore, soluble MCAM promoted 
expression of Ang-2, IL-8 and MMP-9, as well as increased mRNA expression of VEGF in tumour 
cells, indicating pro-angiogenic effects 106. Similarly, Harhouri et al. (2010) showed that 50 
ng/ml of soluble MCAM promoted proliferation, migration and tube formation in late 
endothelial progenitor cells (EPCs) in vitro and showed that soluble MCAM recruited EPCs to 
ischemic mouse tissue and caused increase in vascularization in mouse experimental hind limb 
ischemia 119. The difference between these observations and our experiment could be due to 
different concentrations and recombinant protein tag used. The Fc tag form dimers and it was 
shown that MCAM function can vary depending on dimeric or monomeric form 154,155. Dimeric 
MCAM could sequester binding proteins and thus inhibit their effects on HUVECs 115,156 while 
soluble monomeric MCAM could have a pro-angiogenic properties by binding Angiomotin p80 
on endothelial cells 106. Furthermore, higher concentrations used could initiate opposite 
effects as seen with other proteins such as Netrin-1. Netrin-1 at lower concentrations 
promotes angiogenesis via MCAM binding while it blocks angiogenesis in higher 
concentrations by binding to the UNC5B membrane protein 111,157. Further experiments with 
a range of recombinant MCAM concentrations, as well as recombinant protein with a different 
tag need to be performed in order to identify the cause of these differences. Repeating the 
experiments with deletion constructs of soluble MCAM could show which domain of MCAM 








have been reported for MCAM signalling in angiogenesis have to be performed in order to 
investigate molecular basis of the effects of soluble MCAM on HUVECs. Furthermore, a pull-
down experiment with HUVECs cell lysate and supernatant might shed light to which proteins 
hMCAMecd-Fc binds, however this could be difficult if the interactions are transient or weak.  
Data presented here make a starting point for utilization of soluble MCAM 
extracellular domain as a receptor trap, which could be used as a novel approach for anti-
angiogenic treatment for RCC. Previous attempts to use soluble receptor traps such as 
extracellular domains of EphB4, Tie2 or TGFβ type III receptor inhibited the effects of pro-
angiogenic factors such as VEGF or bFGF and inhibited tumour growth in murine models 158–
160. Soluble EphB4 showed inhibitory effects on tube formation already at a concentration of 
14 nM, and reduced angiogenesis and tumour growth in mouse xengraft tumours 160. Soluble 
ROBO4 inhibited in vivo angiogenesis at a concentration of 1.25 μM 161, while Tie2 receptor 
trap inhibited angiogenesis at a concentration of 3 μM 158. Experiments testing soluble MCAM 
protein in in vivo angiogenesis or murine xengraft tumour models would be crucial in order to 













6.1 Therapeutic potential for targeting MCAM on tumour vessels 
The main goal of this thesis was to explore the possibility of developing strategies to 
therapeutically target MCAM in renal cell carcinoma. Our group was the first to show that 
MCAM was highly expressed on the vasculature of renal cell carcinoma, specifically those of 
clear cell histology 56. The work described in this thesis confirmed those of Wragg et al. (2016) 
by developing a novel monoclonal antibody that localises in vivo to mouse RENCA tumour 
blood vessels.  
Clear cell renal cell carcinomas are known to be highly vascular and previous targeting 
of angiogenesis has proven an effective treatment for these tumours 49,55. Most of these 
therapies target the VEGF pathway and it is now well documented that such therapies can 
cause complicating side effects due to VEGF’s involvement in the maintenance of healthy 
blood vessels 162. Resistance and aggressive recurrence of the cancer are also frequent events 
due to bypassing of the VEGF pathway by, possibly, expression of additional angiogenic factors 
163,164. Indeed, MCAM itself has been reported to aid development of resistance to anti-
angiogenic therapy in RCC. For example, resistance to the widely used anti-angiogenic drug 
sunitinib has been linked to higher levels of MCAM RNA expression in metastatic RCC and an 
increase in soluble MCAM in patients’ plasma 126. Thus, targeting MCAM on tumour blood 
vessels raises the possibility of increased efficacy of established anti-angiogenic therapies.  
It is worthy of note that MCAM involvement in resistance to other chemotherapies has 
been reported in cancers beyond renal cell carcinoma. For example, in breast cancer, high 
expression of MCAM correlated with increased cell surface expression of ErbB3 and ErbB4 and 
increased resistance to doxorubicin and docetaxel chemotherapy 165. In cervical cancer, high 








targeting MCAM with the AA98 monoclonal antibody abrogated the reduced sensitivity to 
radiotherapy, showing that targeting MCAM in combination with other therapies could 
improve cancer treatment. Another study has shown that simultaneous targeting VEGF with 
Bevacizumab and anti-MCAM antibody AA98 gave rise to slower tumour growth in mouse 
xenograft models 108. Having monoclonal antibodies that recognise mouse MCAM will aid 
further studies in mouse models of cancer. Nevertheless, to determine if the mMCAM10 
antibody shows an inhibitory effect on tumour growth, the variable region needs insertion 
into the mouse immunoglobulin main frame so that the antibody can be used in immuno-
competent mice. Although of course it could be studied in human xenografts in SCID mice that 
will not generate antibodies to the rat monoclonal.  
Greater efficacy would probably be seen with an antibody drug conjugate (ADC). ADCs 
are comprised of an antibody to which a toxic drug is attached 167. There are several ADCs in 
clinical development for cancer 168. The first such therapy for RCC (AMG 172) is currently in 
phase I clinical trial (NCT01497821). AMG 172 is the anti-CD27L human monoclonal antibody 
conjugated to the maytansinoid DM1 by a non-cleavable linker. The most important 
requirement of an ADC is high specificity of the antibody in order to prevent toxicities caused 
by binding to healthy tissue 169. The mMCAM10 showed specific tumour vessel, as compared 
to vessels in healthy tissue, localisation one hour after intra venous injection, making it a 
promising tool for an ADC approach.  
 
Another therapeutic approach is to use CAR modified T cells. CAR-T cells represent one 
of the currently most exciting approaches to cancer treatment 170,171. CAR T cell therapy 








recombinant T-cell receptor targeting the antigen of interest. The modified T cells are then 
expanded in vitro and infused back into the patient where they destroy the antigen expressing 
cells 3. Our collaborators from S. Lee’s laboratory cloned the variable region of the mMCAM10 
into the chimeric antigen receptor and introduced it into mouse T-cells. They confirmed that 
the mMCAM10 chimeric antigen receptor conserved specificity to mouse MCAM after cloning. 
Transfected T-cells were shown to be activated by recombinant mMCAM in vitro (S. Lee. 
personal communication). Further work is funded and in progress. 
In humans an anti-MCAM antibody, PRX003, has been used in clinical trials for the 
treatment of psoriasis patients. The rationale for clinical trial of an anti MCAM antibody in 
psoriasis is the expression of MCAM on Th17 T-cells. This subset of T-cells are defined by their 
expression of IL17, and are involved in several autoimmune diseases such as psoriasis and 
multiple sclerosis 172. The expression of MCAM on these cells has been shown to increase their 
ability to bind LAMA4 and cross the endothelium into the inflamed tissue. PRX003 blocks 
MCAM binding to LAMA4, as well as reduces expression of MCAM on treated cells, causing 
inhibition of T-cell transmigration in several animal autoimmune disease models 173. This 
antibody showed no off-target toxicities but reduced psoriasis symptoms by 40-60% when 
used in animals 174. The fact that PRX003 had a desired effect in patients and had no severe 
toxicities, poses a possible proof of concept that anti-MCAM targeted therapy could be a 
promising approach in treatment of cancer 175. Furthermore, combination with immune 
checkpoint inhibitors may possibly benefit MCAM targeting, as these therapies often cause 
autoimmune conditions. Anti-MCAM antibody could thus have a dual purpose: the targeting 








shown that targeting immune checkpoint molecules in RCC treatment gave improved patient 
survival when combined with anti-angiogenics 176.  
Soluble MCAM as a receptor trap to block angiogenesis 
Blocking angiogenesis by targeting the specificity of receptor-ligand interactions using 
soluble receptor traps such as the VEGF receptor trap (aflibercept) has proven an effective 
therapeutic strategy for cancer and other pathologies 177,178. MCAM is implicated in tumour 
angiogenesis and thought to react with several soluble or membrane bound angiogenic 
factors 66,111. Furthermore, it has been shown that galectin-3, a protein that promotes cancer 
progression and metastasis, binds MCAM and initiates its dimerization, which leads to 
activation of ACT kinase 179. This thesis has shown that the MCAM extracellular domain Fc 
fusion protein inhibited the in vitro pro-angiogenic properties of HUVECs. Soluble extracellular 
MCAM shed from endothelium has also been shown to promote angiogenesis and shown to 
be elevated in the plasma of patients with pathologies in which there is increased 
vascularisation 68,69. In contrast to these reports, other groups have shown that the MCAM 
extracellular domain fused to a myc tag and used in lower concentrations had an opposite 
effect on HUVECs and endothelial progenitor cells (EPCs) 106,119. It is possible that the Fc tag, 
which mediates dimerization, could be an explanation for these different observations. 
Recombinant receptor traps have entered the clinic mostly for the treatment of 
immunological diseases. An exception is the VEGF receptor trap Aflibercept (Eylea®, Zaltrap®). 
Aflibercept is comprised of one VEGFR1 domain and one VEGFR2 domain fused to an Fc tag. 
Aflibercept blocks angiogenesis by sequestering VEGF-A, VEGF-B and placental growth factor 
180 and has been FDA approved for the treatment of metastatic colorectal cancer in 








agents the VEGF trap presents the best efficacy, especially in terms of pharmacologic 
properties. The utilisation of the Fc tag has also proven beneficial in such chimeric biological 
drug therapies over un-tagged proteins due to its ability to increase the serum half-life of the 
protein 181. Additionally, the Fc provides several other advantages such as ease of production 
and purification, good solubility and stability and Fc immune effector functions, which could 
be manipulated in order to create more efficient and longer-lasting therapies 182. However, 
due to the immune system engagement with the Fc receptors it is important to closely 
monitor the patients’ responses. Furthermore, even though the receptor and the Fc are 
presumably not immunogenic, the region where the protein and Fc tag are fused could elicit 
immune responses to the novel antigen part 183,184. Future preclinical studies in mouse models 
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